

STIC-ILL

Q11. N36
APD

From: Bansal, Geetha
Sent: Friday, November 10, 2000 10:56 AM
To: STIC-ILL

Please provide copies of:

1. McCormick A A; Kumagai M H; Hanley K; Turpen T H; Hakim I; Grill L K; Tuse D; Levy S; Levy R
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1999 Jan 19) 96 (2) 703-8
2. King C A; Spellerberg M B; Zhu D; Rice J; Sahota S S; Thompsett A R; Hamblin T J; Radl J; Stevenson F K
NATURE MEDICINE, (1998 Nov) 4 (11) 1281-6.
3. ***Idiotypic*** vaccination in B-cell malignancies.
Bianchi A.; Massaia M.
Molecular Medicine Today, (1997) 3/10 (435-441).
4. Stevenson F K; Zhu D; King C A; Ashworth L J; Kumar S; Thompsett A; Hawkins R E
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1995 Nov 27) 772 212-26.

Thanks

Geetha Bansal

1642
CM1/8A03
305-3955

STIC-ILL

From: Bansal, Geetha
Sent: Friday, November 10, 2000 10:56 AM
To: STIC-ILL

Please provide copies of:

1. McCormick A A; Kumagai M H; Hanley K; Turpen T H; Hakim I; Grill L K; Tuse D; Levy S; Levy R

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1999 Jan 19) 96 (2) 703-8

2. King C A; Spellerberg M B; Zhu D; Rice J; Sahota S S; Thompsett A R; Hamblin T J; Radl J; Stevenson F K
NATURE MEDICINE, (1998 Nov) 4 (11) 1281-6.

3. ***Idiotypic*** vaccination in B-cell malignancies.

Bianchi A.; Massaia M.

Molecular Medicine Today, (1997) 3/10 (435-441).

4. Stevenson F K; Zhu D; King C A; Ashworth L J; Kumar S; Thompsett A; Hawkins R E

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1995 Nov 27) 772 212-26.

Thanks

Geetha Bansal

1642
CM1/8A03
305-3955

STIC-ILL

QH506.14654

From: Bansal, Geetha
Sent: Friday, November 10, 2000 10:56 AM
To: STIC-ILL

Please provide copies of:

1. McCormick A A; Kumagai M H; Hanley K; Turpen T H; Hakim I; Grill L K; Tuse D; Levy S; Levy R
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1999 Jan 19) 96 (2) 703-8
2. King C A; Spellerberg M B; Zhu D; Rice J; Sahota S S; Thompsett A R; Hamblin T J; Radl J; Stevenson F K
NATURE MEDICINE, (1998 Nov) 4 (11) 1281-6.
3. ***Idiotypic*** vaccination in B-cell malignancies.
Bianchi A.; Massaia M.
Molecular Medicine Today, (1997) 3/10 (435-441).
4. Stevenson F K; Zhu D; King C A; Ashworth L J; Kumar S; Thompsett A; Hawkins R E
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1995 Nov 27) 772 212-26.

Thanks

Geetha Bansal

1642
CM1/8A03
305-3955

STIC-ILL

From: Bansal, Geetha
Sent: Friday, November 10, 2000 10:56 AM
To: STIC-ILL

NOS

Q11. N4

319734

Please provide copies of:

1. McCormick A A; Kumagai M H; Hanley K; Turpen T H; Hakim I; Grill L K; Tuse D; Levy S; Levy R
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1999 Jan 19) 96 (2) 703-8
2. King C A; Spellerberg M B; Zhu D; Rice J; Sahota S S; Thompsett A R; Hamblin T J; Radl J; Stevenson F K
NATURE MEDICINE, (1998 Nov) 4 (11) 1281-6.
3. ***Idiotypic*** vaccination in B-cell malignancies.
Bianchi A.; Massaia M.
Molecular Medicine Today, (1997) 3/10 (435-441).
4. Stevenson F K; Zhu D; King C A; Ashworth L J; Kumar S; Thompsett A;
Hawkins R E
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1995 Nov 27) 772 212-26.

Thanks

Geetha Bansal

1642
CM1/8A03
305-3955

Agl-500 N484

Agl
11/14
DPS
COMPLETED
16
1244

09/370,453

Page 12

FILE 'HOME' ENTERED AT 10:14:06 ON 10 NOV 2000

=> file medline biosis embase scisearch uspatfull wpids

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.75	0.75

FILE 'MEDLINE' ENTERED AT 10:16:46 ON 10 NOV 2000

FILE 'BIOSIS' ENTERED AT 10:16:46 ON 10 NOV 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 10:16:46 ON 10 NOV 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 10:16:46 ON 10 NOV 2000
COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

FILE 'USPATFULL' ENTERED AT 10:16:46 ON 10 NOV 2000
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 10:16:46 ON 10 NOV 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

=> s B cell lymphoma derived immunoglobulin!

L1 0 B CELL LYMPHOMA DERIVED IMMUNOGLOBULIN!

=> s (vaccine!) and (B cell lymphoma)

L2 256 (VACCINE!) AND (B CELL LYMPHOMA)

=> s 12 and antibod?

L3 164 L2 AND ANTIBOD?

=> s 13 and multivalent vaccine

L4 4 L3 AND MULTIVALENT VACCINE

=> s 13 and (multivalent vaccine)

L5 4 L3 AND (MULTIVALENT VACCINE)

=> d 15 1-4 bib ab

L5 ANSWER 1 OF 4 USPATFULL
AN 2000:47032 USPATFULL
TI Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses
IN Rose, Timothy M., 5045 NE. 70th St., Seattle, WA, United States 98115
Bosch, Marnix L., 2601 78th Ave. NE., Bellevue, WA, United States
98004 Strand, Kurt, 22101 SE. 32 St., Issaquah, WA, United States 98027
PI US 6051375 20000418

Page 1

AI US 1999-301390 19990428 (9)
RLI Division of Ser. No. US 1996-720229, filed on 26 Sep 1996
PRAI US 1995-4297 19950926 (60)
DT Utility
EXNAM Primary Examiner: Mosher, Mary E.; Assistant Examiner: Salimi, Ali R.
LREP Fish & Richardson, P.C.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 7446

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are about 91% identical between RFHV1 and KSHV, and <about.65% identical to that of other gamma herpes viruses. The full-length KSHV Glycoprotein B sequence comprises a transmembrane domain near the N-terminus, and a plurality of potentially antigenic sites in the extracellular domain. Materials and methods are provided to characterize Glycoprotein B encoding regions of members of the RFHV/KSHV subfamily, including but not limited to RFHV1, RFHV2, and KSHV Peptides, polynucleotides, and **antibodies** of this invention can be used for diagnosing infection, and for eliciting an immune response against Glycoprotein B.

L5 ANSWER 2 OF 4 USPATFULL
AN 2000:15318 USPATFULL
TI Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses
IN Rose, Timothy M., Seattle, WA, United States
Bosch, Marnix L., Seattle, WA, United States
Strand, Kurt, Issaquah, WA, United States
PA University of Washington, Seattle, WA, United States (U.S. corporation)
PI US 6022542 20000208
AI US 1996-720229 19960926 (8)
PRAI US 1995-4297 19950926 (60)
DT Utility
EXNAM Primary Examiner: Mosher, Mary E.; Assistant Examiner: Salimi, Ali
LREP Fish & Richardson P.C.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 40 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 6825

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside

the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are about 91% identical between RFHV1 and KSHV, and <.about.65% identical to that of other gamma herpes viruses. The full-length KSHV Glycoprotein B sequence comprises a transmembrane domain near the N-terminus, and a plurality of potentially antigenic sites in the extracellular domain. Materials and methods are provided to characterize Glycoprotein B encoding regions of members of the RFHV/KSHV subfamily, including but not limited to RFHV1, RFHV2, and KSHV Peptides, polynucleotides, and **antibodies** of this invention can be used for diagnosing infection, and for eliciting an immune response against Glycoprotein B.

L5 ANSWER 3 OF 4 USPATFULL
AN 1999:171946 USPATFULL
TI Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses
IN Rose, Timothy M., Seattle, WA, United States
Bosch, Marnix L., Bellevue, WA, United States
Strand, Kurt, Issaquah, WA, United States
PA The University of Washington, Seattle, WA, United States (U.S.
corporation)
PI US 6015565 19990118
AI US 1997-804439 19970221 (8)
RLI Continuation-in-part of Ser. No. WO 1996-US15702, filed on 26 Sep 1996
And a continuation-in-part of Ser. No. US 1996-720229, filed on 26 Sep
1996
PRAI US 1995-4297 19950926 (60)
US 1996-1148 19960711 (60)
DT Utility
EXNAM Primary Examiner: Eisenschenk, Frank C.; Assistant Examiner: Salimi,
Ali
R.
LREP Wetherell, Jr., JohnFish & Richardson P.C.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 34 Drawing Page(s)
LN.CNT 7515
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are about 91% identical between RFHV1 and KSHV, and <.about.65% identical to that of other gamma herpes viruses. The full-length KSHV Glycoprotein B sequence comprises a transmembrane domain near the N-terminus, and a plurality of potentially antigenic sites in the extracellular domain. Materials and methods are provided to characterize Glycoprotein B encoding regions of members of the RFHV/KSHV subfamily, including but not limited to RFHV1, RFHV2, and KSHV Peptides, polynucleotides, and **antibodies** of this invention can be used for diagnosing infection, and for eliciting an immune response against Glycoprotein B.

L5 ANSWER 4 OF 4 USPATFULL
AN 1999:132226 USPATFULL
TI Vaccines for treatment of lymphoma and leukemia
IN Denney, Jr., Dan W., Redwood City, CA, United States
PA Genitope Corporation, United States (U.S. corporation)
PI US 5972334 19991026
AI US 1996-761277 19961206 (8)
RLI Continuation-in-part of Ser. No. US 1996-644664, filed on 1 May 1996,
now patented, Pat. No. US 5776746
DT Utility
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Bansal, Geetha
P.
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 5339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides multivalent vaccines for the
treatment of B-cell malignancies (e.g., lymphomas and leukemias). The
present invention also provides methods for the production of custom
vaccines, including multivalent vaccines for the
treatment of immune cell tumors malignancies as well as methods of
treating immune cell tumors using custom vaccines.

=> dhis

DHIS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (>).

=> d his

(FILE 'HOME' ENTERED AT 10:14:06 ON 10 NOV 2000)

FILE 'MEDLINE, BIOSIS, EMBASE, SCISEARCH, USPATFULL, WPIDS' ENTERED AT
10:16:46 ON 10 NOV 2000

L1 0 S B CELL LYMPHOMA DERIVED IMMUNOGLOBULIN!
L2 256 S (VACCINE!) AND (B CELL LYMPHOMA)
L3 164 S L2 AND ANTIBOD?
L4 4 S L3 AND MULTIVALENT VACCINE
L5 4 S L3 AND (MULTIVALENT VACCINE)

=> s l2 and (idiotyp?)

L6 151 L2 AND (IDIOTYP?)

=> s l3 and l6

L7 116 L3 AND L6

=> s l7 and (recombinant V region!)

L8 0 L7 AND (RECOMBINANT V REGION!)

=> s l7 and (immunoglobulin!)

L9 38 L7 AND (IMMUNOGLOBULIN!)

=> dup rem 19

PROCESSING COMPLETED FOR L9

L10 35 DUP REM L9 (3 DUPLICATES REMOVED)

=> d 110 1-35 bib ab

L10 ANSWER 1 OF 35 USPATFULL
AN 2000:141878 USPATFULL
TI Recombinant anti-CD4 **antibodies** for human therapy
IN Hanna, Nabil, Olivenhain, CA, United States
Newman, Roland Anthony, San Diego, CA, United States
Reff, Mitchell Elliot, San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)
PI US 6136310 20001024
AI US 1995-523894 19950906 (8)
RLI Continuation-in-part of Ser. No. US 1995-476237, filed on 7 Jun 1995,
now patented, Pat. No. US 5756096 which is a continuation-in-part of
Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No.
US 5658570 which is a continuation of Ser. No. US 1992-912292, filed on 10
Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US
1992-856281, filed on 23 Mar 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991,
now abandoned
DT Utility
EXNAM Primary Examiner: Bansal, Geetha P.
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 32 Drawing Page(s)
LN.CNT 3398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Chimeric **antibodies** specific to human CD4 antigen, DNA
encoding, pharmaceutical compositions containing and use thereof as
therapeutic agents are taught. These chimeric **antibodies**
contain Old World monkey variable sequences and human constant domain
sequences, preferably human gamma 1, gamma 4 or mutated forms thereof.
These **antibodies** possess desirable therapeutic properties
including low antigenicity, reduced (or absent) T cell depleting
activity, good affinity to human CD4 and enhanced stability (in vivo
half-life).

L10 ANSWER 2 OF 35 USPATFULL
AN 2000:101879 USPATFULL
TI Enhancement of **B cell lymphoma** and tumor
resistance using **idiotype/cytokine conjugates**
IN Levy, Ronald, Stanford, CA, United States
Tao, Mi-Hua, Taipei, Taiwan, Province of China
PA The Board of Trustees of the Leland Stanford Junior University, Palo
Alto, CA, United States (U.S. corporation)
PI US 6099846 20000808
WO 9408601 19940428
AI US 1995-416787 19950414 (8)
WO 1993-US9895 19931014
19950414 PCT 371 date
19950414 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1992-961788, filed on 14 Oct 1992,
now abandoned
DT Utility
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Nolan,
Patrick
J.

LREP Morrison & Foerster LLP
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 520

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **B cell lymphoma** tumor-associated antigen or a fragment thereof containing an epitope are linked to an immune-enhancing cytokine, such as GM-CSF, IL-2, or IL-4 to form an immuno-complex. This immuno-complex elicits immune responses which are protective with respect to tumor proliferation. The linkers may be simple chemical bifunctional moieties introduced through chemical synthetic techniques or peptides introduce through recombinant methodologies. **Antibodies** immunoreactive with these immunocomplexes are also useful as passive **vaccines** and as analytical tools.

L10 ANSWER 3 OF 35 USPATFULL
AN 2000:54204 USPATFULL
TI Variable heavy and light chain regions of murine monoclonal antibody 1F7
IN Muller, Sybille, Lexington, KY, United States
Kohler, Heinz, Lexington, KY, United States
PA Immpheron, Inc., Lexington, KY, United States (U.S. corporation)
PI US 6057421 20000502
AI US 1997-984277 19971203 (8)
RLI Continuation-in-part of Ser. No. US 1994-351193, filed on 30 Nov 1994, now abandoned

DT Utility
EXNAM Primary Examiner: Burke, Julie
LREP Meadows, James H.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 28 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 2137

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The amino acid sequences of variable heavy and variable light domains of murine monoclonal antibody 1F7 are reported. Methods of use for products containing these sequences in the diagnosis and the treatment of HIV infection and AIDS are also described.

L10 ANSWER 4 OF 35 USPATFULL
AN 2000:47032 USPATFULL
TI Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses
IN Rose, Timothy M., 5045 NE. 70th St., Seattle, WA, United States 98115
Bosch, Marnix L., 2601 78th Ave. NE., Bellevue, WA, United States 98004

Strand, Kurt, 22101 SE. 32 St., Issaquah, WA, United States 98027
PI US 6051375 20000418
AI US 1999-301390 19990428 (9)
RLI Division of Ser. No. US 1996-720229, filed on 26 Sep 1996
PRAI US 1995-4297 19950926 (60)

DT Utility
EXNAM Primary Examiner: Mosher, Mary E.; Assistant Examiner: Salimi, Ali R.
LREP Fish & Richardson, P.C.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 7446

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque

nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are about 91% identical between RFHV1 and KSHV, and <about.65% identical to that of other gamma herpes viruses. The full-length KSHV Glycoprotein B sequence comprises a transmembrane domain near the N-terminus, and a plurality of potentially antigenic sites in the extracellular domain. Materials and methods are provided

to

characterize Glycoprotein B encoding regions of members of the RFHV/KSHV subfamily, including but not limited to RFHV1, RFHV2, and KSHV Peptides, polynucleotides, and **antibodies** of this invention can be used for diagnosing infection, and for eliciting an immune response against Glycoprotein B.

L10 ANSWER 5 OF 35 USPATFULL

AN 2000:24287 USPATFULL

TI Receptor specific transepithelial transport of therapeutics

IN Blumberg, Richard S., Chestnut Hill, MA, United States

Simister, Neil E., Wellesley, MA, United States

Lencer, Wayne I., Jamaica Plain, MA, United States

PA The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)

Brandeis University, Waltham, MA, United States (U.S. corporation)

PI US 6030613 20000229

AI US 1997-899856 19970724 (8)

RLI Continuation-in-part of Ser. No. US 1995-578171, filed on 29 Dec 1995 which is a continuation-in-part of Ser. No. US 1995-374159, filed on 17 Jan 1995, now patented, Pat. No. US 5671273

DT Utility

EXNAM Primary Examiner: Cunningham, Thomas M.

LREP Wolf, Greenfield & Sacks, P.C.

CLMN Number of Claims: 34

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1591

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and

immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and **vaccines**.

L10 ANSWER 6 OF 35 USPATFULL

AN 2000:15318 USPATFULL

TI Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses

IN Rose, Timothy M., Seattle, WA, United States

Bosch, Marnix L., Seattle, WA, United States

Strand, Kurt, Issaquah, WA, United States

PA University of Washington, Seattle, WA, United States (U.S. corporation)

PI US 6022542 20000208
AI US 1996-720229 19960926 (8)
PRAI US 1995-4297 19950926 (60)
DT Utility
EXNAM Primary Examiner: Mosher, Mary E.; Assistant Examiner: Salimi, Ali
LREP Fish & Richardson P.C.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 40 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 6825
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are about 91% identical between RFHV1 and KSHV, and <about.65% identical to that of other gamma herpes viruses. The full-length KSHV Glycoprotein B sequence comprises a transmembrane domain near the N-terminus, and a plurality of potentially antigenic sites in the extracellular domain. Materials and methods are provided to characterize Glycoprotein B encoding regions of members of the RFHV/KSHV subfamily, including but not limited to RFHV1, RFHV2, and KSHV Peptides, polynucleotides, and **antibodies** of this invention can be used for diagnosing infection, and for eliciting an immune response against Glycoprotein B.

L10 ANSWER 7 OF 35 USPATFULL
AN 2000:12608 USPATFULL
TI Methods for determining the presence of carcinoma using the antigen binding region of monoclonal **antibody** BR96
IN Hellstrom, Ingegerd, Seattle, WA, United States
Hellstrom, Karl Erik, Seattle, WA, United States
Bruce, Kim Folger, Seattle, WA, United States
Schreiber, George J., Seattle, WA, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 6020145 20000201
AI US 1994-333840 19941103 (8)
RLI Division of Ser. No. US 1993-77253, filed on 14 Jun 1993 which is a continuation-in-part of Ser. No. US 1993-57444, filed on 5 May 1993, now patented, Pat. No. US 5491088 which is a continuation of Ser. No. US 1990-544246, filed on 26 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-374947, filed on 30 Jun 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.
LREP Merchant, Gould, Smith, Edell, Welter & Schmidt
CLMN Number of Claims: 4
ECL Exemplary Claim: 1,3
DRWN 76 Drawing Figure(s); 74 Drawing Page(s)
LN.CNT 5875
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel **antibodies**,

with antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive

a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

L10 ANSWER 8 OF 35 USPATFULL
AN 1999:171946 USPATFULL
TI Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses
IN Rose, Timothy M., Seattle, WA, United States
Bosch, Marnix L., Bellevue, WA, United States
Strand, Kurt, Issaquah, WA, United States
PA The University of Washington, Seattle, WA, United States (U.S.
corporation)
PI US 6015565 19990118
AI US 1997-804439 19970221 (8)
RLI Continuation-in-part of Ser. No. WO 1996-US15702, filed on 26 Sep 1996
And a continuation-in-part of Ser. No. US 1996-720229, filed on 26 Sep
1996
PRAI US 1995-4297 19950926 (60)
US 1996-1148 19960711 (60)
DT Utility
EXNAM Primary Examiner: Eisenschenk, Frank C.; Assistant Examiner: Salimi,
Ali
R.
LREP Wetherell, Jr., JohnFish & Richardson P.C.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 34 Drawing Page(s)
LN.CNT 7515
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are about 91% identical between RFHV1 and KSHV, and <about.65% identical to that of other gamma herpes viruses. The full-length KSHV Glycoprotein B sequence comprises a transmembrane domain near the N-terminus, and a plurality of potentially antigenic sites in the extracellular domain. Materials and methods are provided to

characterize Glycoprotein B encoding regions of members of the RFHV/KSHV subfamily, including but not limited to RFHV1, RFHV2, and KSHV Peptides, polynucleotides, and **antibodies** of this invention can be used for diagnosing infection, and for eliciting an immune response against Glycoprotein B.

L10 ANSWER 9 OF 35 USPATFULL
AN 1999:141303 USPATFULL
TI **Antibodies** reactive with human carcinomas
IN Hellstrom, Ingegerd, Seattle, WA, United States
Hellstrom, Karl Erik, Seattle, WA, United States
Bruce, Kim Folger, Seattle, WA, United States
Schreiber, George J., Redmond, WA, United States
Siegal, Clay, Edmonds, WA, United States
McAndrew, Stephen, Newtown, PA, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S.
corporation)
PI US 5980896 19991109
AI US 1993-77253 19930614 (8)
RLI Continuation-in-part of Ser. No. US 1993-57444, filed on 5 May 1993,
now patented, Pat. No. US 5491088 And Ser. No. US 1992-892501, filed on 1 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-544246, filed on 26 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-374947, filed on 30 Jun 1989, now abandoned , said Ser. No. US 1993-57444, filed on 5 May 1993, now patented, Pat. No. US 5491088 which is a continuation of Ser. No. US 544246
DT Utility
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.
LREP Merchant, Gould, Smith, Edell, Welter & Schmidt
CLMN Number of Claims: 35
ECL Exemplary Claim: 1,16,34
DRWN 76 Drawing Figure(s); 74 Drawing Page(s)
LN.CNT 5987
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel **antibodies**, **antibody** fragments and **antibody** conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the **antibodies**, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal **antibody**, BR96; a human/murine chimeric **antibody**, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 **antibody** and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate **antibody**-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the **antibodies** of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the **antibody** component of **antibody**-drug or **antibody**-toxin conjugates. The **antibodies** also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

L10 ANSWER 10 OF 35 USPATFULL
AN 1999:137463 USPATFULL
TI Murine anti-**idiotype** antibody 3H1

IN Chatterjee, Malaya, Lexington, KY, United States
Kohler, Heinz, Lexington, KY, United States
Chatterjee, Sunil K., Lexington, KY, United States
Foon, Kenneth A., Lexington, KY, United States
PA The Board of Trustees of the University of Kentucky, Lexington, KY,
United States (U.S. corporation)
PI US 5977315 19991102
AI US 1995-579940 19951228 (8)
RLI Continuation-in-part of Ser. No. US 1994-365484, filed on 28 Dec 1994,
now abandoned
DT Utility
EXNAM Primary Examiner: Reeves, Julie
LREP Morrison & Foerster LLP
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 52 Drawing Figure(s); 43 Drawing Page(s)
LN.CNT 2698

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a monoclonal anti-**idiotype antibody** 3H1 that escapes immune tolerance and elicits a specific immune response to CEA in mice, rabbits, monkeys, and patients with advanced CEA-associated disease. This invention also provides compositions which can be used in the detection or treatment of CEA-associated tumors mimics a specific epitope on carcinoembryonic antigen and a hybridoma that produces 3H1.

L10 ANSWER 11 OF 35 USPATFULL

AN 1999:132226 USPATFULL
TI **Vaccines** for treatment of lymphoma and leukemia
IN Denney, Jr., Dan W., Redwood City, CA, United States
PA Genitope Corporation, United States (U.S. corporation)
PI US 5972334 19991026
AI US 1996-761277 19961206 (8)
RLI Continuation-in-part of Ser. No. US 1996-644664, filed on 1 May 1996,
now patented, Pat. No. US 5776746
DT Utility
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Bansal, Geetha P.
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 5339

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides multivalent **vaccines** for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom **vaccines**, including multivalent **vaccines** for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom **vaccines**.

L10 ANSWER 12 OF 35 USPATFULL

AN 1999:18719 USPATFULL
TI **Antibody conjugates reactive with human carcinomas**
IN Hellstrom, Ingegerg, Seattle, WA, United States
Hellstrom, Karl Erik, Seattle, WA, United States
Bruce, Kim Folger, Seattle, WA, United States
Schreiber, George J., Seattle, WA, United States
PA Bristol-Myers Squibb Company, New York, NY, United States (U.S.
corporation)
PI US 5869045 19990209
AI US 1995-459354 19950602 (8)
RLI Division of Ser. No. US 1993-77253, filed on 14 Jun 1993 which is a continuation-in-part of Ser. No. US 1993-57444, filed on 5 May 1993,
now

patented, Pat. No. US 5491088 which is a continuation of Ser. No. US 1990-544246, filed on 26 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-374947, filed on 30 Jun 1989, now abandoned

DT Utility
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Ungar, Susan
LREP Merchant, Gould, Smith, Welter and Schmidt
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 75 Drawing Figure(s); 74 Drawing Page(s)
LN.CNT 5935

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel **antibodies**, **antibody** fragments and **antibody** conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the **antibodies**, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal **antibody**, BR96; a human/murine chimeric **antibody**, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 **antibody** and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate **antibody**-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the **antibodies** of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the **antibody** component of **antibody**-drug or **antibody**-toxin conjugates. The **antibodies** also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

L10 ANSWER 13 OF 35 USPATFULL
AN 1999:7146 USPATFULL
TI Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
IN Kwak, Larry W., Frederick, MD, United States
Longo, Dan L., Kensington, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5861158 19990119
AI US 1993-153464 19931117 (8)
DT Utility
EXNAM Primary Examiner: Minnifield, Nita
LREP Needle & Rosenberg, P.C.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 732

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a method of improving a transplantation of hematopoietic cells from a donor to a recipient to treat a hematopoietic cell tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's hematopoietic cell tumor, and transplanting the donor's immunized hematopoietic cells to the recipient. Also provided is a composition comprising purified hematopoietic cells primed to produce an immunological response to foreign tumor specific antigen. Also provided is a method of treating a tumor by the transplantation of hematopoietic

cells from a donor to a recipient to treat the tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's tumor, and transplanting the donor's immunized hematopoietic cells to the recipient.

L10 ANSWER 14 OF 35 MEDLINE DUPLICATE 1
AN 1999110954 MEDLINE
DN 99110954
TI Rapid production of specific **vaccines** for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants.
AU McCormick A A; Kumagai M H; Hanley K; Turpen T H; Hakim I; Grill L K;
Tuse D; Levy S; Levy R
CS Biosource Technologies, Inc., 3333 Vacaville Parkway, Suite 1000, Vacaville, CA 95688, USA.
NC CA33399 (NCI)
AI37219 (NIAID)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1999 Jan 19) 96 (2) 703-8.
Journal code: PV3. ISSN: 0027-8424.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 199905
EW 19990503
AB Rapid production of protein-based tumor-specific **vaccines** for the treatment of malignancies is possible with the plant-based transient expression system described here. We created a modified tobamoviral vector
that encodes the **idiotype**-specific single-chain Fv fragment (scFv) of the immunoglobulin from the 38C13 mouse **B cell lymphoma**. Infected Nicotiana benthamiana plants contain high levels of secreted scFv protein in the extracellular compartment. This material reacts with an anti-**idiotype antibody** by Western blotting, ELISA, and affinity chromatography, suggesting that the plant-produced 38C13 scFv protein is properly folded in solution. Mice vaccinated with the affinity-purified 38C13 scFv generate >10 micrograms/ml anti-**idiotype immunoglobulins**. These mice were protected from challenge by a lethal dose of the syngeneic 38C13 tumor, similar to mice immunized with the native 38C13 IgM-keyhole limpet hemocyanin conjugate vaccine. This rapid production system for generating tumor-specific protein **vaccines** may provide a viable strategy for the treatment of non-Hodgkin's lymphoma.

L10 ANSWER 15 OF 35 USPATFULL
AN 1998:147025 USPATFULL
TI Vaccine comprising anti-**idiotypic antibody** to chlamydia GLXA and process
IN MacDonald, Alex Bruce, Amherst, MA, United States
An, Ling-Ling, La Jolla, CA, United States
Sutton-Stuart, Elizabeth, Amherst, MA, United States
Whittum-Hudson, Judith A., Elkton, MD, United States
PA Johns Hopkins University, United States (U.S. corporation)
University of Massachusetts, United States (U.S. corporation)
PI US 5840297 19981124
AI US 1993-34572 19930319 (8)
DT Utility
EXNAM Primary Examiner: Loring, Susan A.
LREP Cook, Paul J.
CLMN Number of Claims: 17
ECL Exemplary Claim: 5
DRWN 17 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 2015

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A genus specific chlamydia vaccine is provided which comprises an anti-**idiotype antibody** capable of producing in an animal an anti-anti-**idiotypic antibody** which recognizes a glycolipid exoantigen (GLXA) of chlamydia. The vaccine is produced by producing an **idiotypic antibody** to GLXA which, in turn, is utilized to produce the anti-**idiotypic antibody** comprising the vaccine.

L10 ANSWER 16 OF 35 USPATFULL

AN 1998:64956 USPATFULL

TI Immunogenic cancer proteins and peptides and methods of use

IN Calenoff, Emanuel, Chicago, IL, United States

PA Northwestern University, Evanston, IL, United States (U.S. corporation)

PI US 5763164 19980609

AI US 1994-191338 19940203 (8)

RLI Continuation-in-part of Ser. No. US 1993-49698, filed on 16 Apr 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Rees, Dianne

LREP Brinks Hofer Gilson & Lione

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 13 Drawing Figure(s); 13 Drawing Page(s)

LN.CNT 2928

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to tumor specific antigens and functional proteins of a tumor cell preparable by identifying protein presents in the tumor cell that are selectively immunogenic for tumor patients. The present invention still further provides a process of making a peptide library of tumor specific humoral antigens, a process of increasing the immunogenic specificity of a tumor-associated antigen, an assay kit for detecting the presence of an **antibody** immunoreactive with a tumor-specific antigen, and a process of making T cells sensitized to a tumor-specific antigen.

L10 ANSWER 17 OF 35 USPATFULL

AN 1998:57523 USPATFULL

TI Recombinant **antibodies** for human therapy

IN Newman, Roland A., San Diego, CA, United States

Hanna, Nabil, Olivenhain, CA, United States

Raab, Ronald W., San Diego, CA, United States

PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)

PI US 5756096 19980526

AI US 1995-476237 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No. US 5658570 which is a continuation of Ser. No.

US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned

DT Utility

EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.

LREP Burns, Doane, Swecker & Mathis, L.L.P.

CLMN Number of Claims: 6

ECL Exemplary Claim: 1,4

DRWN 26 Drawing Figure(s); 26 Drawing Page(s)

LN.CNT 1919

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Chimeric **antibodies** including an Old World monkey portion and a human portion, nucleic acid encoding such **antibodies**, Old

World monkey monoclonal **antibodies**, and methods for their production and use.

L10 ANSWER 18 OF 35 USPATFULL
AN 1998:51191 USPATFULL
TI Recombinant **antibodies** for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5750105 19980512
AI US 1995-476349 19950607 (8)
RLI Division of Ser. No. US 1995-379072, filed on 5 Dec 1995 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.
LREP Burns, Doane, Swecker & Mathis LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 2110
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Chimeric **antibodies** including an Old World monkey portion and a human portion, nucleic acid encoding such **antibodies**, Old World monkey monoclonal **antibodies**, and methods for their production and use.

L10 ANSWER 19 OF 35 USPATFULL
AN 1998:14646 USPATFULL
TI Method for diagnosing a patient for chlamydia
IN MacDonald, Alex Bruce, Amherst, MA, United States
Stuart, Elizabeth S., Amherst, MA, United States
An, Ling Ling, La Jolla, CA, United States
Whipkey, Myron D., Portland, ME, United States
PA Animal House, Inc., Portland, ME, United States (U.S. corporation)
PI US 5716793 19980210
AI US 1995-406113 19950317 (8)
RLI Continuation-in-part of Ser. No. US 1993-34572, filed on 19 Mar 1993
DT Utility
EXNAM Primary Examiner: Spiegel, Carol A.
LREP Cook, Paul J.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of detecting chlamydia in a extracellular sample is provided which comprises contacting the sample with an **idiotypic antibody** to GLXA to form an immunocomplex and detecting the immunocomplex.

L10 ANSWER 20 OF 35 USPATFULL
AN 1998:6785 USPATFULL
TI Induction of cytotoxic T-lymphocyte responses
IN Raychaudhuri, Syamal, San Diego, CA, United States
Rastetter, William H., Rancho Santa Fe, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5709860 19980120
AI US 1994-351001 19941207 (8)

RLI Continuation-in-part of Ser. No. US 1992-919787, filed on 24 Jul 1992 which is a continuation-in-part of Ser. No. US 1991-735069, filed on 25 Jul 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Woodward, Michael P.; Assistant Examiner: Zeman, Mary K.
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1242
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This antigen formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.

L10 ANSWER 21 OF 35 MEDLINE
AN 1999025406 MEDLINE
DN 99025406
TI DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma [see comments].
CM Comment in: Nat Med 1998 Nov;4(11):1239-40
AU King C A; Spellerberg M B; Zhu D; Rice J; Sahota S S; Thompsett A R; Hamblin T J; Radl J; Stevenson F K
CS Tenovus Laboratory, Southampton University Hospitals Trust, England.
SO NATURE MEDICINE, (1998 Nov) 4 (11) 1281-6.
Journal code: CG5. ISSN: 1078-8956.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199902
EW 19990204
AB Vaccination with idiotypic protein protects against B-cell lymphoma, mainly through anti-idiotypic antibody. For use in patients, DNA vaccines containing single-chain Fv derived from tumor provide a convenient alternative vaccine delivery system. However, single-chain Fv sequence alone induces low anti-idiotypic response and poor protection against lymphoma. Fusion of the gene encoding fragment C of tetanus toxin to single-chain Fv substantially promotes the anti-idiotypic response and induces strong protection against B-cell lymphoma. The same fusion design also induces protective immunity against a surface Ig-negative myeloma. These findings indicate that fusion to a pathogen sequence allows a tumor antigen to engage diverse immune mechanisms that suppress growth. This fusion design has the added advantage of overcoming potential tolerance to tumor that may exist in patients.

L10 ANSWER 22 OF 35 USPATFULL
AN 97:114941 USPATFULL
TI Induction of cytotoxic T-lymphocyte responses
IN Raychaudhuri, Syamal, San Diego, CA, United States
Rastetter, William H., Rancho Santa Fe, CA, United States

PA Black, Amelia, Cardiff, CA, United States
IDEc Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)

PI US 5695770 19971209

AI US 1995-472311 19950607 (8)

RLI Continuation of Ser. No. US 1994-351001, filed on 7 Dec 1994 which is a
continuation-in-part of Ser. No. US 1992-919787, filed on 24 Jul 1992,
now patented, Pat. No. US 5585103, issued on 17 Dec 1996 which is a
continuation-in-part of Ser. No. US 1991-735069, filed on 25 Jul 1991,
now abandoned

DT Utility

EXNAM Primary Examiner: Woodward, Michael P.; Assistant Examiner: Zeman, Mary
K.

LREP Burns, Doane, Swecker & Mathis, LLP

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN 19 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 1134

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions useful for inducing a cytotoxic T lymphocyte
response (CTL) in a human or domesticated or agriculturally important
animal. The method includes the steps of providing the antigen to which
the CTL response is desired and providing an antigen formulation which
comprises, consists, or consists essentially of two or more of a
stabilizing detergent, a micelle-forming agent, and an oil. This
antigen
formulation is preferably lacking in an immunostimulating peptide
component, or has sufficiently low levels of such a component that the
desired CTL response is not diminished. This formulation is provided as
a stable oil-in-water emulsion.

L10 ANSWER 23 OF 35 USPATFULL

AN 97:112606 USPATFULL

TI Recombinant **antibodies** for human therapy

IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States

PA Idec Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)

PI US 5693780 19971202

AI US 1995-481869 19950607 (8)

RLI Division of Ser. No. US 1995-379072, filed on 25 Jan 1995 which is a
continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now
abandoned which is a continuation-in-part of Ser. No. US 1992-856281,
filed on 23 Mar 1992, now abandoned which is a continuation-in-part of
Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned

DT Utility

EXNAM Primary Examiner: Scheiner, Toni R.; Assistant Examiner: Bansal, Geetha
P.

LREP Burns, Doane, Swecker & Mathis, LLP

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 26 Drawing Figure(s); 26 Drawing Page(s)

LN.CNT 1755

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Chimeric **antibodies** including an Old World monkey portion and
a human portion, nucleic acid encoding such **antibodies**, Old
World monkey monoclonal **antibodies**, and methods for their
production and use.

L10 ANSWER 24 OF 35 USPATFULL

AN 97:109699 USPATFULL

TI Immunoglobulin superantigen binding to gp 120 from HIV

IN Braun, Jonathan, Sherman Oaks, CA, United States

PA Goodglick, Lee A., Los Angeles, CA, United States
The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 5691135 19971125
AI US 1994-306116 19940914 (8)
RLI Continuation-in-part of Ser. No. US 1994-259669, filed on 14 Jun 1994,
now abandoned which is a continuation of Ser. No. US 1993-9705, filed
on
26 Jan 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner: Stucker,
Jeffrey
LREP Knobbe Martens Olson & Bear, LLP
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 1993
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB VH3 and VH4 type **immunoglobulins** display superantigen-type
binding affinity for the HIV gp120 envelope glycoprotein. VH3 and VH4
type **antibody** molecules, including IgG and IgM, are shown to
suppress HIV infection in vivo and in vitro. Determining the level of
such **antibody** molecules is correlated to the advancement of
HIV disease state.

L10 ANSWER 25 OF 35 USPATFULL
AN 97:99175 USPATFULL
TI Recombinant **antibodies** for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)
PI US 5681722 19971028
AI US 1995-478039 19950607 (8)
RLI Division of Ser. No. US 1995-379072, filed on 25 Jan 1995 which is a
continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now
abandoned which is a continuation-in-part of Ser. No. US 1992-856281,
filed on 23 Mar 1992, now abandoned which is a continuation-in-part of
Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 2117
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Chimeric **antibodies** including an Old World monkey portion and
a human portion, nucleic acid encoding such **antibodies**, Old
World monkey monoclonal **antibodies**, and methods for their
production and use.

L10 ANSWER 26 OF 35 USPATFULL
AN 97:73287 USPATFULL
TI Recombinant **antibodies** for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States
PA Idec Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)
PI US 5658570 19970819
AI US 1995-379072 19950125 (8)
RLI Continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now

abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned

DT Utility
EXNAM Primary Examiner: Feisee, Lila
LREP Burns, Doane, Swecker & Mathis
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 1829

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Chimeric **antibodies** including an Old World monkey portion and a human portion, nucleic acid encoding such **antibodies**, Old World monkey monoclonal **antibodies**, and methods for their production and use.

L10 ANSWER 27 OF 35 USPATFULL
AN 97:70717 USPATFULL
TI Oral vaccine comprising anti-**idiotypic antibody** to chlamydia glycolipid exoantigen and process
IN MacDonald, Alex Bruce, Hatfield, MA, United States
Whittum-Hudson, Judith A., Elkton, MD, United States
Saltzman, William Mark, Baltimore, MD, United States
PA The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
University of Massachusetts, Amherst, MA, United States (U.S. corporation)
PI US 5656271 19970812
AI US 1995-466752 19950606 (8)
RLI Continuation of Ser. No. US 1994-213863, filed on 16 Mar 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-34572, filed on 19 Mar 1993

DT Utility
EXNAM Primary Examiner: Loring, Susan A.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 2188

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A genus specific chlamydia oral or injectable vaccine is provided which comprises an **anti-idiotype antibody** capable of producing in an animal an **anti-idiotypic antibody** or Fab fragment thereof enclosed in microspheres formed of a pharmacologically acceptable polymer is capable of producing in an animal an **anti-anti-idiotypic** immune response (serum **antibody**, secretory **antibody** or T-cell response) which recognizes a glycolipid exoantigen (GLXA) of chlamydia. The oral or injectable vaccine is produced from an **idiotypic antibody** to GLXA which, in turn, is utilized to produce the **anti-idiotypic antibody**.

L10 ANSWER 28 OF 35 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
AN 97316363 EMBASE
DN 1997316363
TI **Idiotypic** vaccination in B-cell malignancies.
AU Bianchi A.; Massaia M.
CS Dr. A. Bianchi, Div. Universitaria di Ematologia, DMOS, AOSGBT, Via Genova
3, 10126 Torino, Italy. maxmass@iol.it
SO Molecular Medicine Today, (1997) 3/10 (435-441).
Refs: 33
ISSN: 1357-4310 CODEN: MMTOFK
PUI S 1357-4310(97)01105-2
CY United Kingdom

DT Journal; General Review
FS 016 Cancer
025 Hematology
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL English
AB Immunoglobulins contain unique portions, collectively termed idiotypes, that can be recognized by the immune system. Idiotypes expressed by tumor cells in B-cell malignancies can be regarded as tumor-specific antigens and targets for vaccine immunotherapy.
Haptens and adjuvants, including cytokines, have been used in several animal models to increase idiotype immunogenicity and establish protective anti-idiotype immunity. These results have been extended by the use of DNA technology, and this has led to the development of a new generation of immunogens, namely fusion proteins and naked-DNA vaccines. The central role of antigen-presenting cells as initiators of anti-idiotype immune responses has also been recognized. Guided by the experimental data, idiotypic vaccination has come into medical use in patients with lymphoma and multiple myeloma.

L10 ANSWER 29 OF 35 USPATFULL
AN 96:116114 USPATFULL
TI Induction of cytotoxic T-lymphocyte responses
IN Raychaudhuri, Syamal, San Diego, CA, United States
Rastetter, William H., Rancho Santa Fe, CA, United States
PA IDEC Pharmaceutical Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5585103 19961217
AI US 1992-919787 19920724 (7)
RLI Continuation-in-part of Ser. No. US 1991-735069, filed on 25 Jul 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Mosher, Mary E.
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1139

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This antigen formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.

L10 ANSWER 30 OF 35 USPATFULL
AN 95:38596 USPATFULL
TI Monoclonal antibody L53 which recognizes a human tumor-associated antigen
IN Hellstrom, Ingegerd, Seattle, WA, United States
Hellstrom, Karl E., Seattle, WA, United States
Marquardt, Hans, Mercer Island, WA, United States
Johnston, Janet, Seattle, WA, United States
PA Oncogen Limited Partnership, United States (U.S. corporation)

PI US 5411884 19950502
AI US 1993-20256 19930218 (8)
RLI Continuation of Ser. No. US 1990-533371, filed on 5 Jun 1990, now abandoned
DT Utility
EXNAM Primary Examiner: Hutzell, Paula K.
LREP Merchant, Gould, Smith, Edell, Welter & Schmidt
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1146
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is concerned with novel monoclonal antibody L53 which binds strongly to a glycoprotein antigen associated with human tumors, including carcinomas of the colon, breast, and lung, as well as melanomas. The antibody binds to normal human cells to a much lesser degree than to tumor cells. The antibody finds use in diagnostic methods for as the detection of malignant cells associated with tumors. Also disclosed is a novel 70,000-75,000 dalton glycoprotein antigen recognized by MAb L53. The L53 antigen is found on the cell surface of human tumor cells. The amino terminal amino acid sequence of this antigen is: ##STR1## in which X represents an unidentified amino acid.

L10 ANSWER 31 OF 35 MEDLINE
AN 96135362 MEDLINE
DN 96135362
TI A genetic approach to **idiotypic** vaccination for **B** cell lymphoma.
AU Stevenson F K; Zhu D; King C A; Ashworth L J; Kumar S; Thompsett A; Hawkins R E
CS Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, United Kingdom.
SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1995 Nov 27) 772 212-26.
Ref: 23
Journal code: 5NM. ISSN: 0077-8923.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals; Cancer Journals
EM 199604
AB **Idiotypic** immunoglobulin expressed by a B cell tumor presents a clear tumor antigen which could be attacked by vaccination of the host. Vaccination with **idiotypic** protein has been shown to induce protective immunity against lymphoma, but application to patients is limited by the requirement of "personal" **vaccines** for each patient. A genetic approach enables V-region sequences encoding **idiotypic** antigen to be rescued from tumor biopsies, and to be assembled as scFv fragments. These can be expressed in bacteria to produce recombinant protein, or used directly as naked DNA **vaccines**. Intramuscular injection of **idiotypic** DNA from a mouse B cell lymphoma induces low levels of syngeneic anti-**idiotypic antibody** in serum. Response can be stimulated by co-injection of DNA plasmids encoding either IL-2 or GM-CSF, and T cells which proliferate in response to **idiotypic** IgM are generated. However, protection against tumor appears to be blocked by continuing secretion of **idiotypic** antigen from the persisting vaccine vector, which forms immune complexes with serum **antibody**. Methods for regulating the level of scFv to engage the immune system,

but not to block the effector arm are being investigated. Similar control will be applicable to the cytokine vectors, which can deliver encoded cytokines designed to activate immune pathways for tumor destruction. Experience gained in lymphoma may be extended to other tumors with defined tumor antigens.

L10 ANSWER 32 OF 35 USPATFULL
AN 93:56702 USPATFULL
TI Anti-idiotype antibodies reactive with shared idiotypes expressed by B cell lymphomas and autoantibodies
IN Miller, Richard A., 8 Ohlone, Portola Valley, CA, United States 94025
PI US 5227159 19930713
AI US 1992-898246 19920612 (7)
RLI Continuation of Ser. No. US 1990-467405, filed on 22 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-304745, filed on 31 Jan 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Lacey, David L.; Assistant Examiner: Budens, Robert D.
LREP Woolcott, Kenneth J.; Burgoon, Jr., Richard P.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB B-cell lymphomas express surface immunoglobulin (immunoglobulin) containing unique **idiotypic (idiotype)** determinants which may be exploited as tumor specific markers. The inventor has produced murine monoclonal **antibodies** (MAbs) reactive with the **idiotype** marker derived from 67 patients with low grade, follicular, small cleaved cell lymphoma. Out of 199 monoclonal **antibodies**, 47 (24%) were found to react with pooled normal human serum immunoglobulin in concentrations ranging from 0.6 .mu.g/ml to 160 .mu.g/ml. Of these 40 monoclonal **antibodies**, 90% cross-reacted with **idiotype** present in normal serum in levels <50 .mu.g/ml. Thirty-two of these anti-**idiotypes** were directed against a shared idiotope expressed on another patient's lymphoma cells. The frequency of shared idiotope expression defined by each **antibody** ranged from 0.26% to 3.9% of the B-cell lymphomas tested. A panel of five anti-**idiotype antibodies** reacted with 80% of AIDS associated lymphomas. Based on the reactivity with these monoclonal **antibodies**, tumors could be grouped into distinct families. In aggregate, these 32 monoclonal **antibodies** reacted with a total of 108 of 332 **B cell lymphoma** cases (32.5%), including 35 of 116 follicular, small cleaved cell lymphomas (30%). Many of these anti-shared idiotypes reacted with more than one histopathologic subtype of lymphoma. Anti-**idiotypes** have been used in **B-cell lymphoma** diagnosis and therapy. Moreover, applicant has discovered at least seven anti-shared **idiotype antibodies** that cross react with autoantibodies, e.g., 16.6 and RF. The development of a library of anti-**idiotypes** reactive with shared idiotypes should facilitate these clinical studies by obviating the need to develop a customized hybridoma for each patient.

L10 ANSWER 33 OF 35 MEDLINE
AN 93226047 MEDLINE
DN 93226047
TI **Idiotype**/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for **B-cell lymphoma** [see comments].
CM Comment in: Nature 1993 Apr 22;362(6422):695

AU Comment in: Nature 1993 Aug 5;364(6437):493
AU Tao M H; Levy R
CS Department of Medicine, School of Medicine, Stanford University,
California 94305.
SO NATURE (1993 Apr 22) 362 (6422) 755-8
Journal code: NSC. ISSN: 0028-0836.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 199307
AB To produce a vaccine against cancer, antigens must be found that are preferentially expressed by tumour cells and can induce an immune response
against the tumour. The variable regions of the immunoglobulin molecules expressed on malignant B cells (idiotypes) are tumour-specific, but are weak immunogens. To induce an immune response in animals or humans, the idiotypic protein has therefore to be chemically coupled to a strongly immunogenic protein and mixed with an adjuvant. The resulting response can protect animals from subsequent tumour challenge, and cure animals with established tumours in combination with chemotherapy. Granulocyte-macrophage colony-stimulating factor (GM-CSF) augments antigen presentation in a variety of cells. Here we show that by fusing a tumour-derived idiotype to GM-CSF, it can be converted into a strong immunogen capable of inducing idiotype-specific antibodies without other carrier proteins or adjuvants and of protecting recipient animals from challenge with an otherwise lethal dose of tumour cells. This approach may be applicable to the design of vaccines for a variety of other diseases.

L10 ANSWER 34 OF 35 USPATFULL
AN 92:102981 USPATFULL
TI Monoclonal antibody to novel antigen associated with human tumors
IN Hellstrom, Ingegerd, Seattle, WA, United States
Hellstrom, Karl E., Seattle, WA, United States
Marquardt, Hans, Mercer Island, WA, United States
PA Oncogen, Seattle, WA, United States (U.S. corporation)
PI US 5171665 19921215
AI US 1989-339142 19890417 (7)
DT Utility
EXNAM Primary Examiner: Kepplinger, Esther L.; Assistant Examiner: Scheiner, Toni R.
LREP Mandel, SaralynnSheldon & Mak
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1173

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is concerned with a novel monoclonal antibody which binds strongly to a protein antigen associated with human tumors, including carcinomas of the colon and lung. The antibody binds to normal human cells to a much lesser degree than to tumor cells. The antibody finds use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. Also disclosed is a novel 66,000 dalton glycoprotein antigen found on the cell surface of human tumor cells. The amino terminal amino acid sequence of this antigen is: ##STR1## in which X represents an unidentified amino acid.

L10 ANSWER 35 OF 35 USPATFULL
AN 92:61852 USPATFULL
TI Monoclonal antibody to novel antigen associated with human

IN tumors
Hellstrom, Karl E., Seattle, WA, United States
Hellstrom, Ingegerd, Seattle, WA, United States
Marquardt, Hans, Mercer Island, WA, United States
Yoneyama, Yoshitaka, Bellevue, WA, United States
PA Oncogen Limited Partnership, Seattle, WA, United States (U.S.
corporation)
PI US 5134075 19920728
AI US 1989-312640 19890217 (7)
DT Utility
EXNAM Primary Examiner: Kepplinger, Esther L.; Assistant Examiner: Bidwell,
Carol E.

LREP Mandel, SaraLynn
CLMN Number of Claims: 21
ECL Exemplary Claim: 8
DRWN No Drawings
LN.CNT 1097

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is concerned with a novel monoclonal antibody which binds strongly to a protein antigen associated with human tumors, including carcinomas of the colon, breast, ovary and lung, as well as melanomas and sarcomas. The antibody binds to normal human cells to a much lesser degree than to tumor cells. The antibody finds use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. Also disclosed is a novel 100,000 dalton glycoprotein antigen found on the cell surface of human tumor cells. The amino terminal amino acid sequence of this antigen is: ##STR1## in which X represents an unidentified amino acid.

=> s B cell lymphoma vaccine!

L11 0 B CELL LYMPHOMA VACCINE!

=> s vaccine comprising immunoglobulin!

L12 0 VACCINE COMPRISING IMMUNOGLOBULIN!

Connecting via Winsock to STN

2 FILES SEARCHED...
 6 FILES SEARCHED...
 L2 1515 L1 AND B (A) CELL

=> S 12 and idiotyp?
 L3 387 L2 AND IDIOTYP?

=> S 13 and variable (a) region
 L4 231 L3 AND VARIABLE (A) REGION

=> S 14 not py=>1996
 '1996: NOT A VALID FIELD CODE

6 FILES SEARCHED...
 L5 40 L4 NOT PY=>1996

=> dup rem 15
 COMMAND INTERRUPTED
 If this message appears repeatedly, please notify the Help Desk.
 Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNNMAIL file.

=> dup rem 15
 COMMAND INTERRUPTED
 If this message appears repeatedly, please notify the Help Desk.
 Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNNMAIL file.

=> d 1-40
 L5 ANSWER 1 OF 40 USPATFULL
 AN 95:82354 USPATFULL
 TI Monoclonal antibodies that bind to soluble IgB but do not bind IgE on IgE expressing B lymphocytes or basophils
 IN Chang, Tse-wen, Houston, TX, United States
 PA Tanox Biosystems, Inc.,
 PI US 5449760 19950912
 AI US 1989-320294 19890306 (7)
 RLI Continuation-in-part of Ser. No. US 1988-291068, filed on 28 Dec 1988, now abandoned which is a continuation-in-part of Ser. No. US 542258 filed on 29 Jul 1988, now a continuation-in-part of Ser. No. US 1987-140036, filed on 31 Dec 1987, now abandoned

DT Utility
 FS Granted
 LN.CNT 726
 INCL INCUM: 530/387 .300
 NCL INCUS: 530/388 .250; 530/389 .300; 435/240 .270
 NCLS: 530/387 .300
 IC NCLM: 530/387 .300
 NCLS: 435/070 .210; 530/388 .250
 [6] ICM: C07K016-18
 ICS: C12N005-10; C12N005-20
 EXP 530/387 .3; 530/388 .25; 435/240 .27; 435/172 .2; 435/70 .21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 40 USPATFULL
 AN 95:50082 USPATFULL
 TI Methods for producing high affinity anti-human IgB-monoclonal antibodies which binds to IgE on IgEbearing B cells but not basophils
 IN Chang, Tse-wen, Houston, TX, United States
 PA Tanox Biosystems, Inc.,
 PI US 542258 19950606
 AI US 1988-228421 19880729 (7)
 RLI Continuation-in-part of Ser. No. US 1987-140036, filed on 31 Dec 1987, now abandoned

DT Utility
 FS Granted
 LN.CNT 110
 INCL INCUM: 435/172 .200
 NCL INCUS: 530/388 .250; 435/240 .270; 435/070 .210
 NCLS: 435/452 .000
 IC NCLM: 435/070 .10; 530/388 .250
 NCLS: 435/070 .16
 ICM: C12N005-06
 ICS: C12N005-20; C07K016-42
 EXP 530/387 .3; 530/388 .25; 435/240 .27; 435/172 .2; 435/240 .27;
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 40 USPATFULL
 AN 95:47846 USPATFULL
 TI Anti-idiotype antibodies specific for the paratope of antibodies which bind to IgE-bearing B cells but not basophils
 IN Chang, Tse-wen, Houston, TX, United States
 PA Sun, Bill N., Houston, TX, United States
 PI Sun, Cecily R., Houston, TX, United States
 PA Tanox Biosystems, Inc.,
 PI US 542051 19950530
 AI US 1989-357483 19890526 (7)
 RLI Continuation-in-part of Ser. No. US 1988-291068, filed on 28 Dec 1988, now abandoned which is a continuation-in-part of Ser. No. US 198-228421, filed on 29 Jul 1988 which is continuation-in-part of Ser. No. US 1987-140036, filed on 31 Dec 1987, now abandoned

DT Utility
 FS Granted
 LN.CNT 1365
 INCL INCUM: 530/387 .200
 NCL INCUS: 530/387 .300; 530/388 .250; 530/388 .730; 435/240 .270
 NCLS: 530/387 .200
 IC NCLM: 530/387 .300
 NCLS: 530/387 .300; 530/388 .250; 530/388 .730
 [6] ICM: C07K016-42

L5 ANSWER 2 OF 40 USPATFULL
 AN 95:56235 USPATFULL
 TI Chimeric anti-human IgB-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE expressing B cells but notto IgE bound to FC receptors on basophils
 IN Chang, Tse-wen, Houston, TX, United States
 PA Tanox Biosystems, Inc.,
 PI US 5428133 19950627
 AI US 1991-809034 19911211 (7)

ICM: C07K016-42

ICS: C12N005-20
EXF 530/387; 530/387.2; 530/388.25; 530/388.73; 435/240.27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 40 USPATFULL
AN 94:70818 USPATFULL
TI Starburst conjugates
IN Kaplan, Donald A.; Midland, MI, United States
Kruiper, Jr.; William J.; Sanford, MI, United States
Tomlinson, Ian A.; Midland, MI, United States
Fazio, Michael J.; Midland, MI, United States
Hedstrand, David M.; Midland, MI, United States
Wilson, Larry R.; Beaverton, MI, United States
PA US 5338532 Continuation-in-part of Ser. No. US 1989-386049, filed on 26 Jul 1989;
US 1991-654851 (7) now abandoned which is a continuation-in-part of Ser. No. US 1987-87266,
filed on 18 Aug 1987, now abandoned which is a continuation-in-part of
Ser. No. US 1986-897455, filed on 18 Aug 1986, now abandoned
Utility Granted
LN.CNT 2745
INCL INCLM: 424/001.490
INCLS: 424/004.000; 424/078.080; 424/078.100; 424/009.000; 424/078.170;
424/078.370; 424/001.530; 424/001.650; 521/025.000;
521/028.000; 436/173.000; 436/806.000; 514/772.100;
514/772.300
NCL NCLM: 424/001.490
NCLS: 424/001.530; 424/001.650; 424/001.690;
424/009.400; 424/009.600; 424/078.080; 424/078.100;
424/078.370; 436/173.000; 436/806.000; 514/772.100;
521/028.000
[5] ICM: A61K043-00
EXF 424/9.83; 424/78.08; 424/78.11; 424/78.37; 424/9.424/639;
424/617; 424/646; 424/641; 424/648; 424/1.1; 424/4; 521/28; 521/25;
424/173; 436/806; 514/772.1; 514/772.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT

L5 ANSWER 6 OF 40 USPATFULL
AN 93:22794 USPATFULL
TI Rodwell, John D.; Yardley, PA, United States
McKearn, Thomas J.; New Hope, PA, United States
Alvarez, Vernon L.; Morrisville, NJ, United States
Radcliffe, Robert D.; Titusville, NJ, United States
Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)
PA PI US 5196510 Continuation-in-part of Ser. No. US 1988-291730, filed on 29 Dec 1988,
US 1990-519702 (7) now abandoned
DT Utility Granted
LN.CNT 1684
INCL INCLM: 530/324.000
INCLS: 530/326.000; 424/001.100; 424/002.000; 436/545.000; 436/546.000
NCL NCLM: 530/324.000
NCLS: 436/545.000; 436/546.000; 530/326.000
[5] ICM: C07K007-08
EXF 436/515; 436/545; 436/546; 530/324.533
436/515; 436/545; 436/546; 530/326; 424/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 40 USPATFULL
AN 91:96281 USPATFULL
TI Anti-idiotype antibodies induced by synthetic polypeptides
IN Carson, Dennis A.; Del Mar, CA, United States
Pong, Sherman, San Diego, CA, United States
Chen, Pojen P.; San Diego, CA, United States
Scripps Clinic and Research Foundation, La Jolla, CA, United States
(U.S. corporation)
PI US 5068177 Continuation-in-part of Ser. No. US 1983-566172, filed on 28 Dec 1983,
AI US 1985/762698 (6) now abandoned
RLI DT Utility Granted
LN.CNT 2606
INCL INCLM: 435/007.920
INCLS: 435/810.000; 435/007.930;
436/518.000; 436/539.000; 436/543.000; 436/547.000; 436/808.000;
514/002.000; 530/324.000; 530/325.000; 530/326.000;
530/327.000; 530/328.000; 530/329.000; 530/330.000; 530/387.000
NCL NCLM: 424/131.00
NCLS: 424/130.100; 424/139.100; 424/158.100; 424/185.100;
424/197.110; 424/810.000; 435/007.920; 435/810.000;
435/965.000; 436/509.000; 436/518.000; 436/539.000; 436/543.000;
436/547.000; 436/808.000; 514/002.000; 530/324.000;
530/325.000; 530/326.000; 530/328.000; 530/329.000;
530/330.000; 530/387.200;
[5] ICM: G01N033-53
EXF ICS: G01N033-53; C07K011-14; C07K007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT

L5 ANSWER 8 OF 40 USPATFULL
AN 88:22113 USPATFULL
TI Anti-immunoglobulin toxin conjugates useful in the treatment of
B cell tumors
IN Uhr, Jonathan W.; Dallas, TX, United States
Vitteta, Ellen S.; Dallas, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United
States (U.S. corporation)
PI US 4792474 Continuation-in-part of Ser. No. US 1981-286090, filed on 23 Jul 1981,
AI US 1983-498754 (6) now abandoned
RLI DT Utility Granted
LN.CNT 893
INCL INCLM: 424/095.910
INCLS: 530/387.000
NCL NCLM: 424/183.100
NCLS: 424/805.000; 424/809.000; 530/387.200;
530/866.000
[4] ICM: A61K039-395
EXF ICS: A61K039-34; C07K015-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT

L5 ANSWER 9 OF 40 USPATFULL
AN 87:53733 USPATFULL
TI Method for the preparation of anti-receptor antibodies
IN Carson, Dennis A.; Del Mar, CA, United States

PA	Scripps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)	1995024221 PCTFULL ED 20020514	AN	TIEN BIOACTIVE AND/OR TARGETED DENDRIMER CONJUGATES CONJUGUES DENDRIMÈRES BIOACTIFS ET/OU CIBLÉS
PI	US 4683295	19870728	TI	DENDRIMERS ET/OU CIBLES
AI	US 1984-614102	19840524 (6)	FR	
DT	Utility		IN	
FS	Granted		BAKER, James, R.;	
LN.CNT	1209		BIEULNSKA, Anna, U.;	
INCL	INC1M: 530/391.000 INC1S: 530/387.-000; 530/388.-000; 424/085.000; 436/547.000; 436/548.000;		BROTHERS, Herbert, M., II;	
	435/068.000		CHENG, Roberta, C.;	
NCLM	424/131.100		FAZIO, Michael, J.;	
NCLS	435/070.300; 435/070.400; 436/547.000; 436/548.000; 530/387.200;		HEDSTRAND, David, M.;	
IC	[4] ICM: C0TK003-08 EXF: 260/112B; 424/85; 436/547; 435/68 CAS INDEXING IS AVAILABLE FOR THIS PATENT.		KAPLAN, Jennifer, A.;	
L5	ANSWER 10 OF 40 PCTFULL COPYRIGHT 2003 Univentio **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER		KLAKAMP, Scott, L.;	
L5	ANSWER 11 OF 40 PCTFULL COPYRIGHT 2003 Univentio TIENT SYNTHETIC VACCINE FOR PROTECTION AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION		KRUPER, William, J., Jr.;	
TI	VACCIN DE SYNTHÈSE PROTÉGANT CONTRE L'INFECTION PAR LE VIH		KUKONSKA-LATALLO, Jolanta;	
IN	HAYNES, Barton, F.;		PIEHIER, Lars, T.;	
PA	PALKER, Thomas, J.		TOMLINSON, Ian, A.;	
LA	DUKE UNIVERSITY		WILSON, Larry, R.;	
DT	English		YIN, Rui	
PT	Patent		THE DOW CHEMICAL COMPANY;	
DS	WO: 9529700	A1 19951109	DENDRITech INCORPORATED;	
AI	WO 1995-US465	A	REGENTS OF THE UNIVERSITY OF MICHIGAN;	
PRAI	US 1994-235,305	19940429	TOMLINSON, Ian, A.;	
ICM	A61K039-21		BAKER, James, R.;	
ICS	C07K014-155; C07K017-02; C07K019-00		BIEULNSKA, Anna, U.;	
L5	ANSWER 12 OF 40 PCTFULL COPYRIGHT 2003 Univentio AN 1995023690 PCTFULL ED 20020514		BROTHERS, Herbert, M., II;	
TIENT	BIOLOGICALLY ACTIVE PEPTIDES AND METHODS OF IDENTIFYING THE SAME		CHENG, Roberta, C.;	
TI	PEPTIDES BIOLÓGICAMENTE ACTIVOS Y MÉTODOS PARA IDENTIFICARLOS		FAZIO, Michael, J.;	
IN	IDENTIFICATION		HEDSTRAND, David, M.;	
VON FELDT, Joen, M.;			KAPLAN, Jennifer, A.;	
KIEBER-EMMONS, Thomas;			KLAKAMP, Scott, L.;	
WEINER, David, B.;			KRUPER, William, J., Jr.;	
WILLIAMS, William, V.			KUKONSKA-LATALLO, Jolanta;	
PA	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE WISTAR INSTITUTE;		PIEHIER, Lars, T.;	
IN	VON FELDT, Joen, M.;		TOMLINSON, Ian, A.;	
KIEBER-EMMONS, Thomas;			WILSON, Larry, R.;	
WEINER, David, B.;			YIN, Rui	
WILLIAMS, William, V.			THE WISTAR INSTITUTE;	
LA	English		LA	
DT	Patent		English	
PI	WO 9529690	A1 19951109	Answer 14 of 40 PCTFULL COPYRIGHT 2003 Univentio	
DS	WO 1995-US160	A	AN 1995015979 PCTFULL ED 20020514	
AI	US 1994-8/235,404	19940429	TIEN PRETARGETING METHODS AND COMPOUNDS	
PRAI	A61K038-00		PROCESSES ET COMPOSÉS DE PRECIBLAGE	
ICM	A61K038-03; A61K038-16;		THEODORE, Louis, J.;	
ICS	C07K007-00; C07K014-00; C07K019-00; C07K016-24;		MEYER, Damon, L.;	
L5	C07K007-08; C07K011-00; C07K014-00; C07K019-00; C07K016-24;		MAILETT, Robert, W.;	
	C07K016-42; C12P021-00; C12P021-02;		KASINA, Suchakar;	
	C12P021-03;		RENO, John, M.;	
			AXWORTHY, Donald, B.;	
			GUSTAVSON, Linda, M.	
			NEOKX CORPORATION	
			English	

DT	PT	FR GB GR IE IT LU MC NL PT SE BF BJ CG CI CM GA GN ML MR		
DS	W:	WO 9515979 CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE	A1	AI WO 1994-AU522 NE SN TD TG
DS	W:	WO 1994-US14174 A 19941207	A1	PRAI AU 1993 PM 1030 A 19940902
DS	W:	US 1993-8/163,188 19931207	A1	ICM 19930906
DS	W:	C07K014-52 C07K014-53; C07K014-54; C07K014-55; C07K016-30; A61K038-17; A61K038-38; A61K051-10	A1	ICM A61K039-395; C07K014-705; C07K001-36; C07K016-42; C12N015-12;
DS	W:	ANSWER 15 OF 40 PCTFULL COPYRIGHT 2003 Univentio	15	ANSWER 18 OF 40 PCTFULL COPYRIGHT 2003 Univentio
DS	W:	1995015770 PCTFULL ED 20020514 METHODS FOR B-CELL POPULATION CONTROL	AN	1995013770 PCTFULL ED 20020514
DS	W:	PRETARGETING METHODS AND COMPOUNDS PROCEDES DE REGULATION DE LA POPULATION DES LYMPHOCYTES B	TIEN	TIEN METHODS FOR B-CELL POPULATION CONTROL
DS	W:	GRAVES, Scott, S.; BHAT, Neelima, M.; BIEBER, Marcia, M.; TENG, Nelson, N. H.	TIIFR	TIIFR PROCEDES DE REGULATION DE LA POPULATION DES LYMPHOCYTES B
DS	W:	BJORN, Michael, J.; BHAT, Neelima, M.; BIEBER, Marcia, M.; TENG, Nelson, N. H.	IN	IN BHAT, Neelima, M.; BIEBER, Marcia, M.; TENG, Nelson, N. H.
DS	W:	RENO, John, M.; AXWORTHY, Donald, B.; FRITZBERG, Alan, R.; THEODORE, Louis, J.	PA	PA THE BOARD OF TRUSTEES OF THE LEELAND STANFORD JUNIOR UNIVERSITY;
DS	W:	NEOX CORPORATION English Patent	LA	LA BIEBER, Marcia, M.; TENG, Nelson, N. H.
DS	W:	WO 9515770 AI 19950615 AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE	PT	PT English Patent
DS	W:	WO 1994-US14223 A 19941209 AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE	PT	PT English Patent
DS	W:	WO 1993-8/164,302 19931209 AI 19950615 AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE	PT	PT English Patent
DS	W:	ANSWER 16 OF 40 PCTFULL COPYRIGHT 2003 Univentio	15	ANSWER 19 OF 40 PCTFULL COPYRIGHT 2003 Univentio
DS	W:	1995015780 PCTFULL ED 20020514 ANTIBODIES THAT MIMIC ACTIONS OF NEUROTROPHINS	AN	1995012423 PCTFULL ED 20020514 METAL RADIONUCLEIDE LABELED PROTEINS FOR DIAGNOSIS AND THERAPY
DS	W:	ANTICORPS IMITANT LES EFFETS DES NEUROTROPHINES CLARY, Douglas, O.; WESTKAMP, Gisella; AUSTIN, Lesann; REICHART, Louis, F.	TIEN	TIEN PROTEINES MARQUÉES AVEC DES RADIONUCLÉIDES MÉTALLIQUES DESTINÉES À UNE UTILISATION DIAGNOSTIQUE ET THÉRAPEUTIQUE
DS	W:	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA English Patent	TIIFR	TIIFR UTILISATION DIAGNOSTIQUE ET THÉRAPEUTIQUE
DS	W:	WO 9515180 AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KR KZ LT MD MG NN SD NO NZ PL PT RO RU SD SE SI SK TT UA UZ VN KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG AI 1994-US13708 A 19941201 AI 1994-US732 CA JP AT BE DK ES DS W: US 1993-8/090,609 19930712 PRAI ICM A61K049-00 ICS A61K043-00	IN	IN FRITZBERG, Alan, R.; KASINA, Sudhakar; GUSTAVSON, Linda, M. NEORX CORPORATION English Patent
DS	W:	ANSWER 17 OF 40 PCTFULL COPYRIGHT 2003 Univentio	15	ANSWER 20 OF 40 PCTFULL COPYRIGHT 2003 Univentio
DS	W:	1995007096 PCTFULL ED 20020514 TREATMENT OF AUTOIMMUNE DISEASE	AN	AN 1994025597 PCTFULL ED 20020513 METHODS AND COMPOSITIONS FOR DETECTION OF SALMONELLA
DS	W:	TRAITEMENT DES MALADIES AUTO-IMMUNES	TIEN	TIEN METHODS AND COMPOSITIONS FOR DETECTION OF SALMONELLA
DS	W:	BERNARD, Claude, Charles, Andre; KERLERO, DE ROSBO, Nicole, Claude, Marie LA TROBE UNIVERSITY;	TIIFR	TIIFR PROCEDURES ET COMPOSITIONS DE DETECTION DE LA SALMONELLE
DS	W:	BERNARD, Claude, Charles, Andre; KERLERO, DE ROSBO, Nicole, Claude, Marie English Patent	IN	IN DORAN, James, L.; KAY, William, W.; COLLINSON, S.; Karen; CLOUTIER, Sharon, C.; KING, Joshua English Patent
DS	W:	WO 9507096 AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KR KZ LT MD MG NN SD NO NZ PL PT RO RU SD SE SI SK TT UA UZ VN KE MW SD AT BE CH DE DK ES	PA	PA UNIVERSITY OF VICTORIA INNOVATION AND DEVELOPMENT CORPORATION; LA DT English Patent
DS	W:	AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KR KZ LT MD MG NN SD NO NZ PL PT RO RU SD SE SI SK TT UA UZ VN KE MW SD AT BE CH DE DK ES	PA	PA A2 19941110 AU BB BG BR BY CA CH CN CZ GE HU JP KG KP KR KZ JK LV MD MG MN MW NO NZ PL PT RO RU SD SE SI SK TT UA UZ VN KE MW SD AT BE CH DE DK ES

				DE CES ANTICORPS
AI	WO 1994-1B205 MR NE SN TD TG A 19940426 PRAI US 1993-8/054, 452 19930426	IN	LEBECQUE, Serge, J., E.; ROUSSET, Francoise, M., E.; BANCHERAU, Jacques	
ICM	CI2R015-31	PA	SCHERING CORPORATION;	
TCI	CI2R001-68; GO1N033-569; C07K013-00; CI2P021-08; CI2Q001-04;		LEBECQUE, Serge, J., E.; ROUSSET, Francoise, M., E.; BANCHERAU, Jacques	
L5	ANSWER 21 OF 40 PCTFULL COPYRIGHT 2003 Univentio	LA		
TIEN AN	ANTIBODIES ANIMAUX TRANSGENIQUES CAPABLES DE PRODUIRE DES ANTICORPS HETEROLOGUES	English		
TIFR IN	NON HUMAN ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS	Patent	A2 19941027 WO 9424164 AU BB BG BR BY CA CN CZ FI GE HU JP KG KR KZ LV MD MG MN MW NO N2 PL PT RO RU SD SI SK TT UA US UZ VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG	
PA IN	KAY, Robert, M.	DS	WO 1994-US3429 A 19940406 A61R039-395; C12P021-08 C07K015-00	
PA IN	LONBERG, Nils;	AI	WO 1993-9340094-A 19930409	
PA IN	RAY, Robert, M.	PRAI		
LA DT	English	ICM		
PI DS	WO 9425585 AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TT UA US UZ VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG	ANSWER 24 OF 40 PCTFULL COPYRIGHT 2003 Univentio AN 1994018345 PCTFULL ED 20020513 AN RECEPTOR-BINDING ANTIROLIFERATIVE PEPTIDES TIERPEPTIDES ANTI-PROLIFERATIFS DE FIXATION DE RECEPTEURS IN RENSCHLER, Markus, F.; LEVY, Ronald; BHATTI, Ramesh, R.; DOWER, William, J.		
AI PRAI	WO 1994-US4580 A 19940425 US 1993-8/053, 131 19930426 US 1993-8/096, 162 19930722 US 1993-8/155, 301 19931118 US 1993-8/161, 739 19931203 US 1993-8/165, 699 19931210 US 1994-8/209, 741 19940309	DT	WO 9418345 AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE DS W: WO 1994-US3119 A 19940204 AI PRAI US 1993-8/014, 426 19930205 IN C12R001-68	
ICM	C12R015-00	Patent	WO 9414469 PCTFULL ED 20020513 AN 1994014469 PCTFULL ED 20020513 AN MULTIVALENT AB1 ANTIBODIES AS VACCINES TIERANTICORPS AB1 MULTIVALENTS UTILISES EN TANT QUE VACCINS IN RODKEY, L.; Scott; IN C12R001-68	
L5	ANSWER 22 OF 40 PCTFULL COPYRIGHT 2003 Univentio	LA	ANSWER 25 OF 40 PCTFULL COPYRIGHT 2003 Univentio AN 1994014469 PCTFULL ED 20020513 AN MULTIVALENT AB1 ANTIBODIES AS VACCINES TIERANTICORPS AB1 MULTIVALENTS UTILISES EN TANT QUE VACCINS IN RODKEY, L.; Scott; IN C12R001-68	
AN TIEN	IMMUNOTHERAPEUTIC PEPTIDES DERIVED FROM TOXIC SHOCK SYNDROME TOXIN-1, ANTIBODIES THERETO, THEIR USES IN PHARMACEUTICAL COMPOSITIONS AND DIAGNOSIS	PA	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	
TIFR IN	PEPTIDES IMMUNOTHERAPEUTIQUES DERIVES DE LA TOXINE-1 DU SYNDROME DU CHOC TOXIQUE, ANTICORPS CONTRE CELLE-CI, LEURS UTILISATIONS DANS DES COMPOSITIONS PHARMACEUTIQUES ET EN DIAGNOSTIC	LA		
IN PA	CHOW, Anthony, W.; KUM, Winnie, W., S. CHOW, Anthony, W.; KUM, Winnie, W., S.	English	PI WO 9414469 AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TT UA US UZ VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG DS W:	
LA DT		PI	WO 1993-US12413 A 19931220 A61R039-385; A61K039-39; C07K017-02 A61R039-385; A61K039-39; C07K017-02	
PI DS	WO 9425483 AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TT UA US UZ VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG	ANSWER 26 OF 40 PCTFULL COPYRIGHT 2003 Univentio AN 1994010294 PCTFULL ED 20020513 AN HUMAN MONOClonAL ANTIBODIES TO HUMAN PARVOVIRUS AND METHODS OF MAKING TIEN AND USING THEREOF TIFR ANTICORPS MONOCLONAUX CONTRE LE PARVOPUS CHEZ L'HOMME, PROCEDES D'OBTENTION ET D'UTILISATION		
AI PRAI ICM	WO 1994-1B140 A 19940503 US 1993-8/058, 518 19930503 C07K007-08 ICM C07K013-00; C12P021-08; A61K037-02; G01N033-50; G01N033-68; A61K039-39	AI	WO 1993-US12413 A 19931220 A61R039-385; A61K039-39; C07K017-02 A61R039-385; A61K039-39; C07K017-02	
L5	ANSWER 23 OF 40 PCTFULL COPYRIGHT 2003 Univentio	LA		
AN TIEN	HUMAN MONOCLONAL ANTIBODIES AND PROCESSES AND MATERIALS FOR MAKING SUCH ANTICORPS MONOCLONAUX HUMAINS, ET PROCESSES ET MATERIAUX DE FABRICATION	English		

IN	ZOLLA-PAZNER, Susan;	AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL RO RU SD SE SK UA US VN AT BE CH DE DK ES FR GB OR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG	DS	W:	AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL RO RU SD SE SK UA US VN AT BE CH DE DK ES FR GB OR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG	
PA	ARAKELOV, Serguei;					
PA	MIROSLAV, Gorni					
PA	NEW YORK UNIVERSITY					
LA	English					
DT	Patient					
PI	WO 9410294	A1 19940511 CA JP AT BE DK ES FR GB GR IE IT LU MC NL PT SE DS	AI	WO 1993-US1014 A 19931022	WO 1993-US1014 A 19931022	WO 1993-US1014 A 19931022
DS	US 1992-7/965,935					
AI	US 1992-7/965,935					
PRAI						
ICM	C12N015-02; A61K039-395; A61K039-42; A61K039-12; G01N033-53					
ICS						
L5	ANSWER 27 OF 40 PCTFULL COPYRIGHT 2003 Univentio					
AN	199409150 PCTFULL ED 20020513					
TIEN	MONOCLONAL ANTIBODIES TO PROSTATE CELLS					
TIFR	ANTICORPS MONOCLONAUX CONTRE LES CELLULES DE LA PROSTATE					
IN	PASTAN, Ira H.					
PA	THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES					
LA	English					
DT	Patient					
PI	WO 9409150	A1 19940428 AU CA JP BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE DS	AI	WO 1993-09166 A 19930922	WO 9312227	WO 9312227
DS	US 1992-7/958,140					
AI	US 1992-7/958,140					
PRAI						
ICM	C12N021-08					
ICS	C12N005-20; A61K039-395; G01N033-574; G01N015-00; C12N001-21; G01N033-58; A61K049-00; C07K015-00; C12N001-21					
L5	ANSWER 28 OF 40 PCTFULL COPYRIGHT 2003 Univentio					
AN	199408008 PCTFULL ED 20020513					
TIEN	IMPROVEMENTS IN OR RELATING TO IMMUNE RESPONSE MODIFICATION					
TIFR	AMELIORATIONS RELATIVES A LA MODIFICATION DE REPONSE IMMUNITAIRE					
IN	HAWKINS, Robert, Edward;					
Russell, Stephen, James;						
STEVENSON, Freda, Katherine;						
WINTER, Gregory, Paul						
PA	MEDICAL RESEARCH COUNCIL;					
HAWKINS, Robert, Edward;						
Russell, Stephen, James;						
STEVENSON, Freda, Katherine;						
WINTER, Gregory, Paul						
LA	English					
DT	Patient					
PI	WO 9408008	A1 19940414 AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG	DS	W:	SUN, Lee, K.; SUN, Bill, N., C.; SUN, Cecily, R., Y.; LIOU, Ruey S.	
AI	WO 1993-CB2054 A 19931004					
PRAI	GB 1992-9220808.1					
ICM	C12N015-13					
ICS	C12N015-62; C12N015-48; C12N015-19; A61K031-70; A61K039-395					
L5	ANSWER 29 OF 40 PCTFULL COPYRIGHT 2003 Univentio					
AN	1993022349 PCTFULL ED 20020513					
TIEN	NATURAL HUMAN IgM ANTIBODIES					
TIFR	ANTICORPS A IgM HUMAINS NATURELS					
IN	RODMAN, Tody, C.					
PA	THE INSTITUTE FOR HUMAN GENETICS AND BIOCHEMISTRY ; RODMAN, Tody, C.					
LA	English					
DT	Patient					
PI	WO 9323349	A1 19931111				

ICS	A61K039-44	PRAI	US 1990-529,186	19900525
L5	ANSWER 32 OF 40 PCTFULL COPYRIGHT 2003 Univentio	ICM	A61K037-02	
AN	1992016553 PCTFULL ED 20020513	L5	ANSWER 35 OF 40 PCTFULL COPYRIGHT 2003 Univentio	
TIEN	MONOCLONAL AND CHIMERIC ANTIBODIES SPECIFIC FOR HUMAN TUMOR NECROSIS FACTOR	AN	1991017173 PCTFULL ED 20020513	
TIFR	ANTICORPS MONOCLONAUX ET CHIMERES DIRIGES SPECIFIQUEMENT CONTRE LE FACTEUR HUMAIN DE NECROSE DE TUMEURS	TIEN	MOLECULAR RECOGNITION UNITS	
IN	LE, Jumming;	TIFR	UNITES DE RECONNAISSANCE MOLECULAIRES	
PA	VILCEK, Jar;	IN	MCKEARN, Thomas, J.;	
LA	DADDONA, Peter, E.;	PA	ALVAREZ, Vernon, L.;	
DT	CHRAYEV, John;	PA	RADCLIFFE, Robert, D.	
PT	KNIGHT, David, M.;	LA	CYTOGEN CORPORATION	
DS	SIEGEL, Scott, A.	English		
AI	NEW YORK UNIVERSITY;	PA		
PRAI	CENTOCOR, INC.	DT		
ICM	English	Patent		
IC	Patent	WO 9117173	A1 19911114	
PT	WO 9216553 A1 19921001	DS	W: AT BE CA CH DE DK ES FR GB GR IT JP LU NL SE	
DS	W: AT AU BE CA CH DB DK ES FR GB GR IT JP LU MC NL SE	AI	WO 1991-US3116 A 19910507	
AI	WO 1992-US2190 A 19920318	PRAI	US 1990-519,702 19900507	
PRAI	US 1991-670,827	ICM	C07H021-00	
ICM	C07K007-00	IC	A61K035-14; A61K037-06	
IC	ICL0039-18; C07K015-28; C12N005-10; C12N015-00; C07H015-12; A61K039-395; G01N033-53	PA		
L5	ANSWER 33 OF 40 PCTFULL COPYRIGHT 2003 Univentio	AN	1991006305 PCTFULL ED 20020513	
AN	199203918 PCTFULL ED 20020513	TIEN	OLIGOMERIC IMMUNOGLOBULINS	
TIEN	TRANSGENIC NON-HUMAN ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES	TIFR	IMMUNOGLOBULINES OLIGOMERES	
TIFR	ANIMAUX NON HUMAINS TRANSGENIQUES CAPABLES DE PRODUIRE DES ANTICORPS HETEROLOGUES	IN	SHUFORD, Walt, W.;	
IN	LONBERG, Nils;	PA	HARRIS, Linda, J.;	
PA	RAY, Robert, M.	LA	RAFF, Howard, V.	
PA	GENPHARM INTERNATIONAL, INC.;	DT	BRISTOL-MYERS SQUIBB COMPANY	
LA	LONBERG, Nils;	Patent		
DT	RAY, Robert, M.	WO 9106105	A1 19910516	
PT	English	DS	W: AT AU BE CA CH DE DK ES FI FR GB GR IT JP KR LU NL NO SE	
PI	Patent	AI	WO 1990-US6426 A 19901106	
DS	WO 9203918 A1 19920319	PRAI	US 1989-432,700 19891107	
W:	AT AT AU BB BE BF BJ BR CA CF CG CH CI CM DE DE DK DK ES ES FI FR GA GB GN GR HU IT JP KP KR LR LU LU MC MG ML	ICM	A61K035-14	
AI	NO 1991 US6185 A 19910828	IC	A61K039-00; A61K039-40; C12N005-02; C12N015-00	
PRAI	US 1990-574,748	PA		
ICM	US 1990-575,962	DT		
IC	19900829	Patent		
PT	19900831	WO 9007713	A1 19900712	
DS		DS	W: AU JP SU	
W:		AI	WO 1989-US5850 A 19891228	
AI		PRAI	US 1998-291,730 19881229	
PRAI		ICM	C01N033-53 A01N063-00	
ICM		IC	C12Q001-68; A01N063-00	
IC		PA		
L5	ANSWER 34 OF 40 PCTFULL COPYRIGHT 2003 Univentio	AN	1990007321 PCTFULL ED 20020513	
AN	1991018618 PCTFULL ED 20020513	TIEN	HOMING SEQUENCES AND THEIR USES	
TIEN	IMMUNOTHERAPEUTIC COMPOSITIONS FOR TREATING AND PREVENTING AIDS, ARC AND HIV INFECTION	TIFR	SEQUENCES DE GUIDAGE ET LEURS EMPLOIS	
TIFR	COMPOSITIONS IMMUNOTHERAPEUTIQUES DE TRAITEMENT ET DE PREVENTION D'INFECTIONS DUES AU SIDA, AU PARA-SIDA ET AU VIH	IN	WEISSMAN, Irving, L.;	
IN	FISHER, Richard, A.;	PA	HOLZMANN, Bernard;	
PA	HESSION, Catherine;	LA	SIEGELMAN, Mark, H.	
LA	BURKY, Linda, C.	English	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY	
DT	BIOGEN, INC.	Patent		
PT	English	WO 9118618 A2 19911212	PA	
DS	AT AU BE BF BJ CA CF CG CH CI CM DE DK ES FR GA GB GR IT JP	LA		
AI	LU ML MR NL SE SN TD TG A 19910523	DT		
AI	WO 1991-US3460 A 19910523	Patent		
		WO 9000712	A1 19900712	

W: AT BE CH DE FR GB IT JP LU NL SE
 AI 1989-05067 A 19891110
 PRAI US 1988-289,201 19881223
 US 1989-315,736 19890224
 ICM A61K00-00

L5 ANSWER 39 OF 40 PCTFULL COPYRIGHT 2003 Univentio
 AN 198906138 PCTFULL ED 20020513
 TIEN UNIQUE ANTIGENIC EPITOPOS ON IgE-BEARING B LYMPHOCYTES
 TIFR EPITOPOS ANTIGENIQUES UNIQUES SUR DES LYMPHOCYTES B PORTEURS
 D'IMMUNOGLOBULINE E
 IN CHANG, Tse-wen;
 SUN, Bill; Nai-Chau;
 PA TANOX BIOSYSTEMS, INC.
 LA English
 DT Patent
 PI WO 8906138 A1 19890713
 DS W- AT AU BE CH DE FR GB IT JP KR LU NL SE SU
 AI WO 1988-US4706 A 19881229
 PRAI US 1987-140,036 19871231
 US 1988-226,421 19880729
 US 1988-229,178 19880805
 US 1988-272,243 19881116
 US 1988-291,068 19881228
 ICM A61K039-395
 ICS C12P021-00; A61K047-00; C12N005-00; C12N015-00

L5 ANSWER 40 OF 40 PCTFULL COPYRIGHT 2003 Univentio
 AN 19850102309 PCTFULL ED 20020507
 TIEN ANTI IDIOTYPE ANTIBODIES INDUCED BY SYNTHETIC POLYPEPTIDES
 TIFR SYNTHETIQUES INDUITS PAR DES POLYPEPTIDES
 IN CARSON, Dennis, A.;
 HOUGHTON, Richard;
 CHEN, Pojen, P.;
 VAUGHAN, John, H.;
 LERNER, Richard, A.;
 FONG, Sherman;
 NMILLIAN, Seamus, L., H.
 SCRIPPS CLINIC AND RESEARCH FOUNDATION
 LA English
 DT Patent
 PI WO 8502909 A1 19850704
 DS W- AT AU BE CH DE FR GB JP LU NL SE
 AI WO 1984-US2116 A 19831228
 PRAI US 1983-566,172 19831228
 ICM C01N033-54

ABFR De nouveaux anticorps monoclonaux oligomères avec une avidité élevée pour des antigènes typiquement de la classe de IgG, sont secrètes avec deux ou plusieurs monomères associés d'immunoglobuline de façon à former des molécules tétravalentes ou hexavalentes d'IgG. On peut former les oligomères en reproduisant essentiellement des régions de la chaîne lourde, notamment la région variable. Les anticorps oligomères de l'isotype de l'IgG traversent le placenta et peuvent transmettre une immunité passive à un fœtus, ce qui est particulièrement important pour protéger des nouveaux-nés contre des agents pathogènes tels que des streptocoques du groupe B.

=> s bispecific and antibody
 L6 11149 BISPECIFIC AND ANTIBODY

<----User Break----->

SEARCH ENDED BY USER

=> s 16 and b(a)cell
 2 FILES SEARCHED...
 6 FILES SEARCHED...
 L7 4150 L6 AND B (A) CELL

=> s 17 and recombinan?
 L8 3559 L7 AND RECOMBINAN?

=> dup rem 18 PROCESSING IS APPROXIMATELY 21% COMPLETE FOR L8
 PROCESSING IS APPROXIMATELY 41% COMPLETE FOR L8
 PROCESSING IS APPROXIMATELY 53% COMPLETE FOR L8
 PROCESSING IS APPROXIMATELY 67% COMPLETE FOR L8
 PROCESSING IS APPROXIMATELY 77% COMPLETE FOR L8
 PROCESSING IS APPROXIMATELY 88% COMPLETE FOR L8
 PROCESSING IS APPROXIMATELY 88% COMPLETE FOR L8
 PROCESSING IS APPROXIMATELY 88% COMPLETE FOR L8
 L9 3535 DUP REM L8 (24 DUPLICATES REMOVED)

=> s 19 not yp=>1996
 1996, NOT A VALID FIELD CODE
 1996, NOT A VALID FIELD CODE
 1996, NOT A VALID FIELD CODE
 <----User Break----->

SEARCH ENDED BY USER

=> s 19 not py=>1996
 1996, NOT A VALID FIELD CODE
 6 FILES SEARCHED...
 COMMAND INTERRUPTED
 REENTER FILE 'MEDLINE', 'CANCERLIT', 'BIOSIS', 'SCISEARCH', 'EMBASE', 'USPPATFULL',
 PCTFULL,
 Oligomers, typically of the IgG class, are secreted having two or more immunoglobulin monomers associated together to form tetravalent or hexavalent IgG molecules. The oligomers can be formed by substantially duplicating regions of the light chain, particularly the variable region. Oligomeric antibodies of the IgG isotype cross the placenta and can provide passive immunity to a fetus, which is particularly important for protecting newborns against pathogens such as group B streptococci.

=> d his
 THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
 Some commands only work in certain files. For example, the EXPAND

command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

```

=> FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, SCISEARCH, EMBASE, USPATFULL, PCTFULL
' MEDLINE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):BYE
'BYE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):quit
'QUIT' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):end
=> file medline, cancerlit, uspatfull, pctfull, scisearch
COST IN U.S. DOLLARS          SINCE FILE      TOTAL SESSION      59.46      59.67
FULL ESTIMATED COST
```

FILE 'MEDLINE' ENTERED AT 12:12:58 ON 03 APR 2003

FILE 'CANCERLIT' ENTERED AT 12:12:58 ON 03 APR 2003

FILE 'USPATFULL' ENTERED AT 12:12:58 ON 03 APR 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 12:12:58 ON 03 APR 2003

COPYRIGHT (C) 2003 Univentio

=> s l10 and b(a)cell
 2 FILES SEARCHED:..
L11 3932 L10 AND B(A) CELL
=> s l11 not PY=>1996
L12 293 L11 NOT PY=>1996
=> s l12 and cytokine
L13 92 L12 AND CYTOKINE
=> d 1-92
L13 ANSWER 1 OF 92 MEDLINE

AN 96141137 MEDLINE
DN 96141137 PubMed ID: 8950837
TI Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
AU Haagen I A
CS Department of Immunology, University Hospital Utrecht, The Netherlands.
SO LEUKEMIA AND LYMPHOMA, (1995 Nov) 19 (5-6) 381-93. Ref: 160
Journal code: 9007422. ISSN: 1042-8194.
CY Switzerland
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(EDITORIAL, ACADMIC)
LA English
FS Priority Journals
EM 199604
ED Entered STN: 19960418
Last Updated on STN: 19970203
Entered Medline: 19960494

AN 96129473 MEDLINE
DN 96129473 PubMed ID: 8981375
TI T cell activation and cytokine production in anti-CD3
AU Belani R; Weiner G J
CS Department of Internal Medicine, University of Iowa, Iowa City 52242, USA.
NC CA5178 (NCI)
SO JOURNAL OF HEMATOThERAPY, (1995 Oct) 4 (5) 395-402.
Journal code: 9306048. ISSN: 1061-6128.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199603
ED Entered STN: 19960327
Last Updated on STN: 19970203
Entered Medline: 19960320

AN 95154184 MEDLINE
DN 95154184 PubMed ID: 7543021
TI CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.
AU de Gast G C; Haagen I A; Klein S C; Duits A J; de Weger R
A; Vroom T M; Clark M R; Phillips J; van Dijk A J; +
CS Department of Immunology, University Hospital Utrecht, The Netherlands.
SO CANCER IMMUNOLOGY, IMMUNOTHERAPY, (1995 Jun) 40 (6) 390-6.
Journal code: 8605732. ISSN: 0340-7004.
CY GERMANY; Germany, Federal Republic of
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; AIDS
EM 199509
ED Entered STN: 19950921
Last Updated on STN: 19980206
Entered Medline: 19950907

AN 95235428 MEDLINE
DN 95235428 PubMed ID: 7719227
TI Bispecific monoclonal antibody therapy of B-cell malignancy.
AU Weiner G J; De Gast G C

		General Review; (REVIEW) (REVIEW, ACADEMIC)
CS	Department of Internal Medicine, University of Iowa, Iowa City 52242, USA.	
SO	LEUKEMA AND LYMPHOMA. (1995 Jan) 16 (3-4) 199-207. Ref: 54	
Journal code: 9007422. ISSN: 1042-8194.		
CY	Switzerland	
DT	Journal; Article; (JOURNAL ARTICLE)	
Entered STN: 19950605		
Entered Medline: 19950605		
Last Updated on STN: 19950605		
Entered Medline: 19950533		
L1.3	ANSWER 5 OF 92 MEDLINE	
AN	94243817 MEDLINE	
DN	94243817 PubMed ID: 8187084	
TI	Role of T-cell subsets in the bispecific antibody (anti-idiotypic x anti-CD3) treatment of the BC11 lymphoma.	
AU	Deranquet C; Brissinck J; Leo O; Moser M; Thielemans K	
CS	Laboratory of Physiology, Medical School of the Vrije Universiteit Brussel (VUB), Belgium.	
SO	CANCER RESEARCH. (1994 Jun 1) 54 (11) 2973-8.	
CY	United States	
DT	Journal; Article; (JOURNAL ARTICLE)	
LA	English	
FS	Priority Journals	
BM	199406	
ED	Entered STN: 19940629	
Last Updated on STN: 19970203		
Entered Medline: 19940621		
L1.3	ANSWER 6 OF 92 MEDLINE	
AN	93115244 MEDLINE	
DN	93115244 PubMed ID: 768689	
TI	CD3-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.	
CM	Eratum in: INT J CANCER. 1994 Apr 15;57 (2):94	
AU	Pohl C; Denfeld R; Remmer C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwoenz M; Diehl V; +	
CS	Klinik I fur Innere Medizin, Universitat zu Koln, Cologne, Germany.	
SO	INTERNATIONAL JOURNAL OF CANCER. (1993 Jul 9) 54 (5) 820-7.	
CY	United States	
DT	Journal; Article; (JOURNAL ARTICLE)	
LA	English	
FS	Priority Journals	
EM	199308	
ED	Entered STN: 19930820	
Last Updated on STN: 19980206		
Entered Medline: 19930812		
L1.3	ANSWER 7 OF 92 CANCERLIT	
AN	96141137 CANCERLIT	
DN	96141137 PubMed ID: 8590837	
TI	Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.	
AU	Hagen I A	
CS	Department of Immunology, University Hospital Utrecht, The Netherlands.	
SO	LEUKEMIA AND LYMPHOMA. (1995 Nov) 19 (5-6) 381-93. Ref: 160	
Journal code: 9007422. ISSN: 1042-8194.		
CY	Switzerland	
DT	Journal; Article; (JOURNAL ARTICLE)	
Entered STN: 19970528		
Last Updated on STN: 19970509		
Entered Medline: 19960528		
L1.3	ANSWER 8 OF 92 CANCERLIT	
AN	96129473 CANCERLIT	
DN	96129473 PubMed ID: 8381375	
TI	T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.	
AU	Betani P; Weiner G J	
CS	Department of Internal Medicine, University of Iowa, Iowa City 52242, USA.	
NC	CA55178 (NCI)	
SO	JOURNAL OF HEMATOOTHERAPY. (1995 Oct) 4 (5) 395-402.	
CY	Journal code: 9306048. ISSN: 1061-6126.	
DT	Journal; Article; (JOURNAL ARTICLE)	
LA	English	
FS	Priority Journals	
OS	MEDLINE 96129473	
EM	199603	
ED	Entered STN: 19960424	
Last Updated on STN: 19970509		
Entered Medline: 19960424		
L1.3	ANSWER 9 OF 92 CANCERLIT	
AN	95554184 CANCERLIT	
DN	95554184 PubMed ID: 7543021	
TI	CD3 T cell activation after intravenous administration of CD3 x CD19 lymphoma.	
AU	de Gast G C; Haagen I A; van Houtens A A; Klein S C; Duits A J; de Weger R A; Vroom T M; Clark M R; Phillips J; van Dijk A J; +	
CS	Department of Immunology, University Hospital Utrecht, The Netherlands.	
SO	CANCER IMMUNOLOGY, IMMUNOTHERAPY. (1995 Jun) 40 (6) 390-6.	
Journal code: 8605732. ISSN: 0340-7004.		
CY	Germany; Federal Republic of	
DT	(CLINICAL TRIAL)	
LA	Journal; Article; (JOURNAL ARTICLE)	
FS	Priority Journals; AIDS	
OS	MEDLINE 95354184	
EM	199509	
ED	Entered STN: 19951012	
Last Updated on STN: 19960517		
Entered Medline: 199509		
L1.3	ANSWER 10 OF 92 CANCERLIT	
AN	95235428 CANCERLIT	
DN	95235428 PubMed ID: 7719227	
TI	Bispecific monoclonal antibody therapy of B-cell malignancy.	
AU	Weiner G J; De Gast G C	
CS	Department of Internal Medicine, University of Iowa, Iowa City 52242, USA.	
SO	LEUKEMIA AND LYMPHOMA. (1995 Jan) 16 (3-4) 199-207. Ref: 54	
CY	Journal code: 9007422. ISSN: 1042-8194.	
DT	Journal; Article; (JOURNAL ARTICLE)	
LA	English	
FS	Priority Journals	
OS	MEDLINE 95235428	

EM 199505 United States 94080
 ED Entered STN: 19950608 Kim, Kyung J., 460 Point San Bruno Blvd., South San Francisco, CA,
 Last Updated on STN: 19950608 United States 94080
 AN 94243817 CANCERLIT Lee, James, 460 Point San Bruno Blvd., South San Francisco, CA, United
 L1.3 ANSWER 11 OF 92 CANCERLIT States 94080
 AN 94243817 PubMed ID: 8187084 PI US 5440021 19950808
 DN 94243817 PubMed ID: 8187084 AI US 5942056 19940225 (8)
 TI Role of T-cell subsets in the bispecific antibody
 (anti-idiotypic x anti-CD3) treatment of the BCCL lymphoma.
 AU Demanet C; Brissinck J; Leo O; Moser M; Thiлеманс K
 CS Laboratory of Physiology, Medical School of the Vrije Universiteit Brussels
 (VUB), Belgium.
 SO CANCER RESEARCH, (1994 Jun 1) 54 (11) 2973-8.
 Journal code: 2984705R. ISSN: 0008-5472.
 CY United States DT Continuation-in-part of Ser. No. US 1991-677211, filed on 29 Mar 1991,
 now abandoned.
 DT Journal Article: (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 OS MEDLINE: 94243817
 EM 199406
 ED Entered STN: 19941107
 Last Updated on STN: 19970509
 L1.3 ANSWER 12 OF 92 CANCERLIT
 AN 9315244 CANCERLIT
 DN 9315244 PubMed ID: 7686889
 TI CD30-antigen specific targeting and activation of T cells via murine
 bispecific monoclonal antibodies against CD3 and CD28:
 potential use for the treatment of Hodgkin's lymphoma.
 CM Eratium in: Int J Cancer 1994 Apr 15;57(2):94
 AU Pohl C; Denfeld R; Renner G; Jung W; Bohlen H; Sahin U; Hombach A; van
 Lier R; Schworzen M; Diehl V; +
 CS Klinik I für Innere Medizin, Universität zu Köln, Cologne, Germany.
 SO INTERNATIONAL JOURNAL OF CANCER, (1993 Jul 9) 54 (5) 820-7.
 CY United States DT Journal Article: (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 OS MEDLINE: 9315244
 EM 199308
 ED Entered STN: 19941107
 Last Updated on STN: 19960517
 L1.3 ANSWER 13 OF 92 CANCERLIT
 AN 92279009 CANCERLIT
 DN 92279009
 TI FUNCTIONAL STUDIES OF HUMAN IgG FC RECEPTORS.
 AU Erbe D V
 CS Dartmouth Coll.
 SO Disc Abstr Int [B], (1991) 52 (3) 1335.
 ISSN: 0419-4217.
 DT Thesis
 LA English
 FS Institute for Cell and Developmental Biology
 EM 199204
 ED Entered STN: 19941107
 Last Updated on STN: 19941107
 L1.3 ANSWER 14 OF 92 USPATFULL
 AN 9517471 USPATFULL
 TI Antibodies to human IL-8 type B receptor
 IN Chuncharapai, Anan, 460 Point San Bruno Blvd., South San Francisco, CA,
 United States 94080
 Hebert, Caroline, 460 Point San Bruno Blvd., South San Francisco, CA,
 United States 94080
 United States 94080
 Kim, Kyung J., 460 Point San Bruno Blvd., South San Francisco, CA,
 United States 94080
 Lee, James, 460 Point San Bruno Blvd., South San Francisco, CA, United
 States 94080
 PI US 5440021 19950808
 AI US 5942056 19940225 (8)
 RLI Continuation-in-part of Ser. No. US 1991-677211, filed on 29 Mar 1991,
 now abandoned.
 DT Utility
 FS Granted
 LN.CNT 2693
 INCL INCLM: 530/388.220
 NCL INCLS: 530/388.230; 530/389.100;
 NCIS: 530/388.220
 NCLS: 530/388.230; 530/389.100;
 IC [6] ICM: C07K016-28
 ICS: C07K016-28; C12N005-22
 EXF ICS: C07K016-28; C12N005-22
 424/158.1; 530/388.73; 530/388.23; 530/389.2; 530/388.33; 530/389.1;
 435/240.27
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1.3 ANSWER 15 OF 92 USPATFULL
 AN 94160277 USPATFULL
 TI Carbohydrate-directed cross-linking reagents
 IN Ashkenazi, Avi J.; San Mateo, CA, United States
 Chamow, Steven M.; San Mateo, CA, United States
 Kogan, Timothy P.; Sugar Land, TX, United States
 PA GentenTech, Inc., San Francisco, CA, United States (U.S. corporation)
 PI US 5329028 19940712
 AI US 1992-926077 19920805 (7)
 DT Utility
 FS Granted
 LN.CNT 1001
 INCL INCLM: 548/548-000
 NCL INCLS: 548/536.000; 548/547.000; 548/549.000
 NCIS: 548/548.000
 NCLS: 548/546.000; 548/547.000;
 IC [5] ICM: C07D207-452
 EXF ICM: C07D207-452
 548/546; 548/547; 548/548; 548/549
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L1.3 ANSWER 16 OF 92 USPATFULL
 AN 93116591 USPATFULL
 TI Hybrid tryptophan aporepressor containing ligand binding sites
 IN Lernhardt, Waldemar, Solana Beach, CA, United States
 Bourdon, Mario, San Diego, CA, United States
 Youderian, Phil, Ramona, CA, United States
 PA California Institute of Biological Research, La Jolla, CA, United States
 (U.S. corporation)
 PI US 5190873 19930302
 AI US 1991-720222 19910621 (7)
 DT Utility
 FS Granted
 LN.CNT 2112
 INCL INCLM: 435/177.000
 NCL INCLS: 435/069.700; 435/069.100; 530/350.000; 530/812.000; 930/250.000
 NCIS: 435/177.000
 NCLS: 435/069.100; 435/069.700; 530/350.000; 530/812.000; 930/250.000
 IC [5] ICM: C07K017-00
 ICS: C07K017-00; C07K017-02; C12P021-00
 EXF ICS: C07K017-00; C07K017-02; C12P021-00
 435/91; 435/69.7; 435/69.1; 435/177; 530/350; 530/812; 930/250

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

- L1.3 ANSWER 17 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
- L1.3 ANSWER 18 OF 92 PCTFULL COPYRIGHT 2003 Univentio
*** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
- L1.3 ANSWER 19 OF 92 PCTFULL COPYRIGHT 2003 Univentio
*** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
- L1.3 ANSWER 20 OF 92 PCTFULL COPYRIGHT 2003 Univentio
*** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
- L1.3 ANSWER 21 OF 92 PCTFULL COPYRIGHT 2003 Univentio
*** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
- L1.3 ANSWER 22 OF 92 PCTFULL COPYRIGHT 2003 Univentio
*** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
- L1.3 ANSWER 23 OF 92 PCTFULL COPYRIGHT 2003 Univentio
*** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
- L1.3 ANSWER 24 OF 92 PCTFULL COPYRIGHT 2003 Univentio
*** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
- L1.3 ANSWER 25 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1995034324 PCTFULL ED 20020514
TIEN CROSS-REACTING MONOCLONAL ANTIBODIES SPECIFIC FOR E-SELECTIN
AND P-SELECTIN IN
ANTICORPS MONOCLONAUX CROISES SE LIANT SPECIFIQUEMENT A LA SELECTINE E
ET A LA SELECTINE P
- IN BERG, Ellen, L.
PA PROTEIN DESIGN LABS, INC.;
LA English
DT Patent
PI WO 9534324
DS W:
- AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LV MD MG MN MW NO NZ PL PT RO RU SD SE SG SI SK TU TM TT UA VN KE UW SD SZ VG
- AI WO 1995 US7302 A1 19951221
PRAI US 1994-8/259,-563
ICM C07K016-00; C07K016-18; C07K016-28; C12N005-10;
TCS C12N005-16; C12N015-13; C12P021-08
- L1.3 ANSWER 26 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1995034320 PCTFULL ED 20020514
TIEN METHODS FOR INHIBITING ANTIGEN SPECIFIC T CELL RESPONSES A UN
PROCEDES D'INHIBITION DES REPONSES DES LYMPHOCYTES T SPECIFIQUES A UN
ANTIGENE
- IN BLAZAR, Bruce, R.;
VALLETA, Daniel, A.
PA REGENTS OF THE UNIVERSITY OF MINNESOTA
LA English
DT Parent
PI WO 9534320
DS W:
AI WO 1995-US7351 A 19950607
PRAI US 1994-8/255,-267
ICM A61K039-00
ICS C07K014-705; C07K014-725; C07K019-00
- L1.3 ANSWER 27 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1995033828 PCTFULL ED 20020514
TIEN MODIFIED CELLS AND METHODS FOR INHIBITING HYPERACUTE REJECTION OF
XENOGENIC TRANSPLANTS
- IN EDGE, Albert
PA DIACRIN, INC.
LA English
DT Patent
PI WO 9534828
DS W:
AI WO 1995-US5973 A 19950517
PRAI US 1994-8/253,-782
ICM C12N005-11
ICS C12N005-06; C12N005-10; A61K035-407; A61K035-44; A61K038-47
- L1.3 ANSWER 28 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1995033823 PCTFULL ED 20020514
TIEN METHODS FOR SELECTIVELY STIMULATING PROLIFERATION OF T CELLS
PROCEDES DE STIMULATION SELECTIVE DE LA PROLIFERATION DES CELLULES T.
IN JUNE, Carl, H.;
THOMPSON, Craig, B.;
NABEL, Gary, J.;
GRAY, Gary, S.;
RENNERT, Paul, D.;
FREEMAN, Gordon, J.
PA THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE NAVY;
THE REGENTS OF THE UNIVERSITY OF MICHIGAN;
REPLICEN CORPORATION;
DANA-FARBER CANCER INSTITUTE
LA English
DT Parent
PI WO 9533823
DS W:
AI WO 1994-US13782 A 19941201
PRAI US 1994-8/253,-751
ICM C12N005-08
ICS G01N033-569; A61K035-14; A61K048-00; C07K016-28; C12N005-20;
C07R014-705
- L1.3 ANSWER 29 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1995033819 PCTFULL ED 20020514
TIEN CDKA (CYCLIN DEPENDENT KINASE 4), BINDING PROTEINS
PROTEINES SE FIXANT A LA CDK4 (KINASE CYCLINO-DEPENDANTE DE TYPE 4)
IN DRAETTA, Giulio;
GYURIS, Jeno
MITOTIX, INC.
PA English
LA English
DT Parent
PI WO 9533819
DS W:
AI WO 1995-US7113 A 19950602
PRAI US 1994-8/253,-155
ICM C12N015-12
ICS C07R014-47; C07K016-18; A01K067-027; G01N033-68; C12Q001-68
- L1.3 ANSWER 30 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1995033370 PCTFULL ED 20020514
TIEN LIGANDS FOR INDUCTION OF ANTIGEN SPECIFIC APOPTOSIS IN T CELLS
LIGANDS POUR L'INDUCTION D'UNE APOPOSE SPECIFIQUE A UN ANTIGENE DANS
LES LYMPHOCYTES T
IN GRIBBEN, John, G.;

- TIEN TIFR METHODS FOR INDUCING T CELL TOLERANCE TO A TISSUE OR ORGAN GRAFT
PROCEDES SERVANT A PROVOQUER LA TOLERANCE DES LYMPHOCYTES A UNE GREFFE
DE TISSU OU D'ORGANE
- IN NOELLE, Randolph, J.;
DURIE, Fiona, H.;
PARKER, David, C.;
APPEL, Michael, C.;
PHILLIPS, Nancy, E.;
MORDES, John, P.;
GRENIER, Dale, L.;
ROSSINI, Aldo, A.
- PA TRUSTEES OF DARTMOUTH COLLEGE;
UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER;
- AI WO 1995-06726 A1 19951214 BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
US 1994-8/253,783 19950602
PRAI ICM C07K014-705
ICM C07K016-28; A61K039-395; A61K038-17
- PA TRUSTEES OF DARTMOUTH COLLEGE;
UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER;
- AI WO 1995-06726 A1 19951214 BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
US 1994-8/253,783 19940603
PRAI ICM C07K014-705
ICM C07K016-28; A61K039-395; A61K038-17
- LA English
DAWN FARMER CANCER INSTITUTE
- DT Patent
PI WO 1995-033052 PCTFULL ED 20020514
AN TIEN ANSWER 31 OF 92 PCTFULL COPYRIGHT 2003 Univentio
TIEN IMMUNOSUPPRESSANT TARGET PROTEINS
PROTEINES CIBLES IMMUNODEPRESSIVES
IN BERLIN, Viviane;
CHIU, Marie, Isabel;
COTTAREL, Guillaume;
DAMAGNEZ, Veronique
PA MITOTIX, INC.
LA English
DT Patent
PI WO 1995-03052 A1 19951207 AU CA JP KR AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
US 1995-056722 A 19950520
PRAI AI WO 1995-06726 A1 19951207 BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
US 1994-8/250,795 19940527
PRAI ICM C12B015-12
ICM C12B015-31; C12N015-62; C12N015-81; C12N001-19; C07K014-47;
ICM C07K014-40; C07K016-18; C12N001-68; G01N033-53
- LA English
DAWN FARMER CANCER INSTITUTE
- DT Patent
PI WO 1995-03015 PCTFULL ED 20020514
AN TIEN ANSWER 32 OF 92 PCTFULL COPYRIGHT 2003 Univentio
TIEN ISOLATED EPSTEIN-BARR VIRUS BZF2 PROTEINS THAT BIND MHC CLASS II BETA
CHAINS PROTEINES BZF2 DU VIRUS D'EPSTEIN-BARR ISOLEES SE LIANT AUX CHAINES
'beta' DU COMPLEXE MAJEUR D'HISTOCOMPATIBILITE DE CLASSE II
IN ALDRIDGE, Mark;
ARMITAGE, Richard, J.;
COHEN, Jeffrey, I.;
COMEAU, Michael, R.;
FARAH, Theesa, M.;
HUTT-FLETCHER, Lindsey, M.;
SPRIGGS, Melanie, K.
IMMINEX CORPORATION;
THE CURATORS OF THE UNIVERSITY OF MISSOURI;
NATIONAL INSTITUTES OF HEALTH
- LA English
DT Patent
PI WO 1995-030015 A2 19951109 AU CA FI JP KR MX NO NZ AT BE CH DE DK ES FR GB GR IE IT LU
MC NL PT SE
AI WO 1995-055348 A 19950428
PRAI ICM C12B015-62
ICM C07K014-05; A61K039-245; C07K016-00
- LA English
DAWN FARMER CANCER INSTITUTE
- DT Patent
PI WO 1995-028957 PCTFULL ED 20020514
AN TIEN ANSWER 33 OF 92 PCTFULL COPYRIGHT 2003 Univentio
- TIEN TIFR METHODS FOR INHIBITING ENDOTHELIAL CELL AND FIBRINOGEN
COMPOSITIONS D'INHIBITION DE L'INFLAMMATION INDUITE PAR LES
CELLULES ENDOTHELIALES ET LE FIBRINOGENE
- IN ALTIBRI, Dario, C.;
LANGUINO, Lucia, R.;
THORNTON, George, B.
PA THE SCRIPPS RESEARCH INSTITUTE
LA English
DT Patent
PI WO 1995-03015 PCTFULL ED 20020514
AN TIEN ANSWER 34 OF 92 PCTFULL COPYRIGHT 2003 Univentio
TIEN METHODS AND COMPOSITIONS FOR INHIBITING ENDOTHELIAL CELL AND FIBRINOGEN
MEDiated INFLAMMATION
COMPOSITIONS D'INHIBITION DE L'INFLAMMATION INDUITE PAR LES
CELLULES ENDOTHELIALES ET LE FIBRINOGENE
- IN ALTIBRI, Dario, C.;
LANGUINO, Lucia, R.;
THORNTON, George, B.
PA THE SCRIPPS RESEARCH INSTITUTE
LA English
DT Patent
PI WO 1995-028957 PCTFULL ED 20020514
AN TIEN ANSWER 35 OF 92 PCTFULL COPYRIGHT 2003 Univentio
TIEN BIOLOGICAL MARKERS OF BENIGN PROSTATE HYPERPLASIA
MARQUEURS BILOGIQUES DE L'HYPERPLASIE BENIGNE DE LA PROSTATE
- IN WRIGHT, George, L., Jr.
PA MEDICAL COLLEGE OF HAMPTON ROAD;
LA English
DT Patent
PI WO 9527075 A1 19951012
W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS

- JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK TT UA UG US UZ VN KE MW SD S2 UG AT
BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI
CM CM GA GN ML MR NE SN TD TG
- AI WO 1995-US424 A 19950330 A 19940331
PRAI US 1994-8/221,921 ICM C07K016-18; C12N005-10; C07K014-47; G01N033-577; A61K039-395;
ICM A61K047-48
- L1.3 ANSWER 36 OF 92 PCTFULL COPYRIGHT 2003 Univentio
TEN GENETICALLY MODIFIED CELLS FOR USE IN TRANSPLANTATION
TIFR CELULES GENETIQUEMENT MODIFIEES EN VUE D'UNE TRANSPLANTATION
IN SCOTT, Michael; CHAPPEL, Scott, C.
PA DIACRIN, INC.
LA DT English
PT Patent
DS WO 9527042 A1 19951012
AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
US 1995-US4060 A 19950330
US 1994-8/221,404 19940331
ICM C12N005-10
ICM A61K035-34; A61K048-00
- L1.3 ANSWER 37 OF 92 PCTFULL COPYRIGHT 2003 Univentio
TEN IMPROVED METHODS FOR TRANSPLANTATION USING MODIFIED CELLS AND T CELL
INHIBITORY AGENTS
TIFR PROCESSES AMELIORES DE TRANSPLANTATION A L'AIDE DE CELLULES MODIFIEES ET
D'AGENTS INHIBITEURS DE LYMPHOCYTES T
IN FRASER, Thomas
PA DIACRIN, INC.
LA English
DT Parent
PI WO 9526740 A1 19951012
AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
US 1994-8/220,724 19940331
PRAI A61K035-39
ICM A61K038-13; A61K038-13; A61K035-39; A61K031-445;
ICM A61K035-39; A61K031-32; A61K035-39; A61K031-37; A61K035-39;
ICM A61K031-675
- L1.3 ANSWER 38 OF 92 PCTFULL COPYRIGHT 2003 Univentio
TEN NUCLEOTIDE OR NUCLEOSIDE PHOTOAFFINITY COMPOUND MODIFIED
ANTIODIADS, METHODS FOR THEIR MANUFACTURE AND USE THEREOF
TIFR ANTICORPS MODIFIES PAR DES COMPOSES DE PHOTOAFFINITE NUCLEOTIDIQUES OU
NUCLEOSIDIQUES, LEURS PROCESSES DE FABRICATION ET D'UTILISATION
IN HALEY, Boyd, E.; KOHLER, Heinz;
RAJAGOPALAN, Krishnan;
PAVLINKOVA, Gabriela
PA THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
LA English
DT Patent
PI WO 9524417 A1 19950914
DS W: AU CA JP NZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1995-US3160 A 19950313
PRAI US 1994-8/208,822 19940313
ICM C07K001-13
ICM C07K001-107; C07K016-00; C07K017-00; C12Q001-25; G01N033-53
- L1.3 ANSWER 39 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1995024217 PCTFULL ED 20020514
TIEN METHODS FOR MODULATING T CELL UNRESPONSIVENESS
TIFR PROCEDES DE MODULATION DE L'ENERGIE DES CELLULES T
IN BOUSSIOUD, Vassiliki, A.; FREEMAN, Gordon, J.;
NADLER, Lee, M.; NADLER, Lee, M.
LA English
PT Patent
DS WO 9524217 A1 19950914
AU CA JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1995-US2916 A 19950308
US 1994-8/207,932 19940308
ICM A61K039-395
ICM C12N005-00; C12N005-10
- L1.3 ANSWER 40 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1995023465 PCTFULL ED 20020514
TIEN ANTI-IL-6 MONOCLONAL ANTIBODIES FOR TREATMENT OF INFLAMMATORY
DISORDERS
TIFR ANTICORPS MONOCLONAUX ANTI-IL-6 POUR LE TRAITEMENT DES TROUBLES
IN DOERSCHUK, Claire, M.; FONG, Sherman;
HERBERT, Caroline, Alice;
KIM, Kyung, Jin;
LEONG, Steven, R.
GENENTECH, INC.; INDIANA UNIVERSITY FOUNDATION
LA English
PT Patent
DS WO 9523865 A1 19950908
CA JP MX AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1995-US2589 A 19950301
US 1994-8/205,864 19940303
ICM C12N015-70
ICM C07K016-24; C12N015-13; C12P021-08; A61K039-395
- L1.3 ANSWER 41 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1995021618 PCTFULL ED 20020514
TIEN IMMUNOMODULATION USING NKR-P1, CD69 AND LIGANDS THEREFOR
IN FEIZI, Teni;
BEZOUSSI, quest; KA, Karel
MEDICAL RESEARCH COUNCIL;
FEIZI, Teni;
BEZOUSSI, quest; KA, Karel
LA English
PT Patent
DS WO 9521618 A1 19950817
AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP
KE KG KP KW KK LR LL LU MD NG MN MW MX NL NO NZ PL PT
RO RU SD SE SI SK TJ TT UA UG US UZ VN KE MW SD UG AT BE
CH DE DK ES FR GB IE IT LU MC NL PT SE BF BJ CF CG CI CM
AI WO 1995-GB21 A1 19950215
GB 1994-942890-9 A 19940215
GB 1994-9412952-5 19940628
GB 1994-9422584-4 19941109
ICM A61K031-70
ICM A61K031-725; A61K031-715

- L1.3 ANSWER 42 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN NOVEL CELL SURFACE RECEPTOR, ANTIBODY COMPOSITIONS, AND
 TIEN METHODS OF USING SAME
 TIFR NOUVEAU RECEPTEUR DE SURFACE CELLULAIRE, COMPOSITIONS D'ANTICORPS ET
 PROCÉDÉS UTILISANT UN TEL RECEPTEUR
 IN ALBERTI Dario, C.
 PA THE SCRIPPS RESEARCH INSTITUTE
 LA English
 DT Patent
 PI WO 9520655 A1 19950803
 DS W: AU CA FI JP NO AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT
 SE
 AI WO 1995-US666 PRAI A 19950118
 US 1994-8/189,309 A 19940128
 ICM C12N015-12
 ICS C07K014-705; C07K016-28; A61K039-395; G01N033-577; G01N033-68
- L1.3 ANSWER 43 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 1995019181 PCTFULL ED 20020514
 TIEN A METHOD OF TREATMENT OF PARASITIC INFECTION USING IGE ANTAGONISTS
 IN PROCÈDE DE TRAITEMENT DE LA PARASITOSE À L'AIDE D'ANTAGONISTES DE L'IGE
 AMIRI, Payman;
 HAAK-FRENDSHO, Mary;
 JARDIEU, Paula, M.
 PA GENENTECH, INC.
 LA English
 DT Patent
 PI WO 9519181 A1 19950720
 DS W: JP MX KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL
 AI WO 1995-US87 PTAI A 1995105
 US 1994-8/184,083 A 19940118
 ICM A61K039-395
 ICS A61K038-17
- L1.3 ANSWER 44 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 1995018974 PCTFULL ED 20020514
 TIEN UBIQUITIN CONJUGATING ENYMES
 TIFR ENZYMES CONJUGUANT L'UBIQUITINE
 IN DRAETTA, Giulio;
 ROLFE, Mark;
 ECKSTEIN, Jens, W.;
 COTTAREL, Guillaume;
 MITOTIX, INC.
 PA MITOTIX, INC.
 LA English
 DT Patent
 PI WO 9518974 A2 19950713
 DS W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 AI WO 1995-US164 PRAI A 19950104
 US 1994-8/176,937 A 19940104
 ICM 19940523
 US 1994-8/247,304 19940527
 US 1994-8/250,795 19940527
 US 1994-8/305,520 19940913
 ICS G01N033-58
 C07K016-40; C12N015-52; C12N001-04; G01N033-50; C12N009-00;
 C12N001-68; C12Q001-68
- L1.3 ANSWER 45 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 1995018858 PCTFULL ED 20020514
 TIEN THROMBOPOIETIN
 TIFR THROMBOPOIETINE
 IN EATON, Dan, L.;
- DE SAUVAGE, Frederic, J.
 GENENTECH, INC.;
 EATON, Dan, L.;
 DE SAUVAGE, Frederic, J.
 English
 Patent
 WO 9518858 A1 19950713
 DS W: AM AU BB BG BR BY CA CH CN C2 DE DK EE ES FI GB GE HU PT RO
 KE KG KP KR KZ LR LT LU MD MG MN MW NL NO NZ PL PT SD
 RU SD SE SI SK TT UA US US US US US US VN KE IE IT LU MC NL PT SE BF EU CF
 CG CI CM GA GN ML MR NE SN TD TG
 AI WO 1994-US14553 PRAI A 19941228
 US 1994-8/116,553 US 19940103
 US 1994-8/185,607 19940121
 US 1994-8/156,689 19940215
 US 1994-8/223,263 19940404
 US 1994-8/249,376 19940525
 US 1994-8/348,557 19941202
 US 1994-8/348,558 19941202
 ICM C12N015-19
 ICS C07K014-52; C07K016-24; A61K038-19
- L1.3 ANSWER 46 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 1995016036 PCTFULL ED 20020514
 TIEN IEN - gamma RECEPTOR 'beta'-CHAIN AND DERIVATIVES THEREOF
 CHAINE - beta - DE RECEPTEURS D'IFN-`gamma` ET LEURS DERIVES
 IN AGUET, Michel;
 Boehrli, Ruth;
 Hemmi, Silvio
 PA
 LA English
 DT Patent
 PI WO 9516036 CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 DS W: WO 1994-US14277 PRAI A 19941207
 AI US 1993-8/164,596 ICM C12N015-12 19931209
 ICS C07K014-715; C12N015-62; C07K016-28; C12N005-10; A61K038-17;
 A61K039-395; C12Q001-68
- L1.3 ANSWER 47 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 1995015979 PCTFULL ED 20020514
 TIEN PRETARGETTING METHODS AND COMPOUNDS
 PROCESSES ET COMPOSÉS DE PRÉCIBLAGE
 IN THEODORE, Louis, J.;
 MEYER, Damon, L.;
 MALETT, Robert, W.;
 KASINA, Sudhakar;
 RENO, John, M.;
 AXWORTHY, Donald, B.;
 GUSTAVSON, Linda, M.
 NEORYX CORPORATION
 PA
 LA English
 DT Patent
 PI WO 9515979 A1 19950615
 DS W: CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 AI WO 1994-US14174 PRAI A 19941207
 US 1993-8/163,188 ICM C07K014-52 19931207
 ICS C07K014-525; C07K014-53; C07K014-54; C07K014-555;
 C07K016-00; C07K016-30; A61K038-17; A61K051-10

- L1.3 ANSWER 48 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN WO 1995015976 PCTFULL ED 20020514
 TIEN A1 1994-08-16
 THEREFOR PCTFULL
 TIFR ICM
 MAISON NUCLEIQUES CODANT UN ALLERGENE D'ACARIENS DE LA POUSSIÈRE DE
 IN A01N063-00; A61K031-70; C07K016-00; C07K016-18;
 "THOMAS, Wayne, R.;
 CHUA, Kaw-Tan;
 ROGERS, Bruce, L.;
 KUO, Mei-chang
- PA ICM
 IMMUNOLOGIC PHARMACEUTICAL CORPORATION;
 INSTITUTE FOR CHILD HEALTH RESEARCH
 LA English
 DT Patent
 PI WO 9515976 A1 19950615
 DS AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP
 KE KG KP KR KZ LK LR LT LU MD MG MN MW NL NO NZ PL PT RO
 RU SD SE SI SK TJ TT UA UZ VN KE MW SD SZ AT BE CH DE DK ES
 FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR
 NE SN TD TG
- AI WO 1994-US14073 A 19941207
 PRAI US 1993-8/163,919 19931208
 ICM C07K014-435
- L1.3 ANSWER 49 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN WO 199501541 PCTFULL ED 20020514
 TIEN A1 1994-08-16
 THEREFOR PCTFULL
 TIFR ICM
 ANTICORPS DIRIGÉS CONTRE L'ANTIGENE CARCINO-EMBRYONNAIRE (CEA)
 IN A61K031-70; C07K016-00; C12N005-10
- PA ICM
 CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED;
 CHESTER, Kerry, Anne;
 HAWKINS, Robert, Edward;
 BEGENT, Richard, Henry, John
 English
 DT Patent
 PI WO 9515341 A1 19950608
 DS W: AU CA HU JP KR NZ US AT BE CH DE DK ES FR GB GR IE IT LU MC
 NL PT SE
- AI WO 1994-GB2658 A 19941205
 PRAI ICM C07K016-30
 ICS A61K039-95; A61K047-48; A61K051-10; C07K016-00; C12N015-13; C12N015-63
- L1.3 ANSWER 50 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN WO 1995015084 PCTFULL ED 20020514
 TIEN A1 1994-08-16
 THEREFOR PCTFULL
 TIFR ICM
 NOUVELLES PROTEINES MODULANT L'APOTOSE, ADN CODANT POUR CES PROTEINES, ET LEUR MODE D'UTILISATION
 IN A61K038-705; C07K016-28; C12N005-10; C12N015-62; A61K035-12;
 BARR, Phillip, J.
 LXK BIOTECHNOLOGY INC.;
 KIEFER, Michael, C.;
 BARR, Phillip, J.
- LA English
 DT Patent
 PI WO 9515084 A1 19950608
 DS W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP
 KE KG KP KR KZ LK LR LT LU MD MG MN MW NL NO NZ PL PT RO
 RU SD SE SI SK TJ TT UA UZ VN KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
- A1 WO 1994-08-16
 PRAI US 1993-8/160,067
 ICM A01N043-04
 ICS C12N001-08; C12N001-21; C12N005-00; C12N005-06; C12N005-16;
- L1.3 ANSWER 51 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 1995013095 PCTFULL ED 20020514
 TIEN TIFR IN
 SMITH, Gary, Keith;
 BLUMENKOPF, Todd, Andrew;
 CORY, Michael;
 THE WELLCOME FOUNDATION LIMITED;
 SMITH, Gary, Keith;
 BLUMENKOPF, Todd, Andrew;
 CORY, Michael
- LA English
 DT Patent
 PI WO 9513095 A2 19950518
 DS W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
- A1 WO 1994-GB2483 A 19941112
 PRAI ICM A61K047-48
 ICS C12N009-64; C12N015-52; C12N015-63; C12N005-10
- L1.3 ANSWER 52 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 1995003,08 PCTFULL ED 20020514
 TIEN B7-2; CTR A3/CD 28 COUNTER RECEIVER
 TIFR B7-2; CONTRÉ-RECEPTEUR DE CTLA4/CD28
 IN FREEMAN, Gordon, J.;
 NADLER, Lee, M.;
 GRAY, Gary, S.;
 GREENFIELD, Edward
 DANA FARBER CANCER INSTITUTE;
 REPLIGEN CORPORATION
 English
 DT Patent
 PI WO 9503408 A1 19950202
 DS W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 AI WO 1994-08-160,624 A 19940726
 PRAI US 1993-8/101,393 19930726
 US 1993-8/109,393 19930819
 C12N015-12
 ICS C07K014-705; C07K016-28; C12N005-10; C12N015-62; A61K035-12;
 A61K038-17; A01K067-07; G01N033-68
- L1.3 ANSWER 53 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 1994029436 PCTFULL ED 20020513
 TIEN METHODS FOR SELECTIVELY STIMULATING PROLIFERATION OF T CELLS
 PROCEDES DE STIMULATION SELECTIVE DE LA PROLIFERATION DES LYMPHOCYTES T
 IN THOMPSON, Carl, H.;
 NABEL, Gary, J.;
 GRAY, Gary, S.;
 PENNERT, Paul, D.
 THE UNITED STATES OF AMERICA represented by THE SECRETARY OF THE NAVY;
 THE REGENTS OF THE UNIVERSITY OF MICHIGAN;

	TU TT UA US US UZ VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE	
REPLIGEN CORPORATION		
English		
LA DT Patent	A1 19941222 AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE	WO 1994-AU117 A 19940311
PI WO 9429436	A1 1994-US6255 A 19940603	US 1993-8/031-141
DS WO 1994-US6255	A 19940603	US 1993-8/081-540
AI PRAI C12N015-08	C12N015-20; C12N005-20; C12N021-08; A61K037-02	C12N015-12 C12N013-68; C07K013-00; A61K039-35
ICM ICS		
L1.3 ANSWER 54 OF 92 PCTFULL COPYRIGHT 2003 Univentio	ANSWER 57 OF 92 PCTFULL COPYRIGHT 2003 Univentio	L1.3 ANSWER 57 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1994025047 PCTFULL ED 20020513	TIEN ALLERGENIC PROTEINS AND PEPTIDES FROM DOG DANDER AND USES THEREFOR UTILISATEUR ASSOCIES	AN 1994016068 PCTFULL ED 20020513
TIEN INHIBITION OF LEUCOCYTE ADHESION	MORENSTEIN, Jay P.; KONIECZNY, Andrzej;	TIEN ALLERGENIC PROTEINS AND PEPTIDES FROM DOG DANDER AND USES THEREFOR UTILISATEUR ASSOCIES
IN LASKY, Laurence, A.; BAUMHUETER, Susanne; ROSEN, Steven, D.; SINGER, Mark, S.	BRAUER, Andrew, W.	TIEN ALLERGENIC PROTEINS AND PEPTIDES FROM DOG DANDER AND USES THEREFOR UTILISATEUR ASSOCIES
PA GENENTECH, INC.; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; LASKY, Laurence, A.; BAUMHUETER, Susanne; ROSEN, Steven, D.; SINGER, Mark, S.	LA English	PA IMMULOGIC PHARMACEUTICAL CORPORATION;
LA DT Patent	WO 9416068	PA MORGENSTEIN, Jay, P.; KONIECZNY, Andrzej;
PI WO 9425047	A1 19941110 AU CA JP KR US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE	PA BIZINKAUSKAS, Christine, B.; BRAUER, Andrew, W.
DS WO 9425047	AI 1994-US3791 A 19940406	LA Patent
AI WO 1993-8/056,454	19930503	WO 19940721
ICM A61K037-02		AU CA JP KR US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
ICM ICS	C07K013-395; C07K015-00	AI 1993-1230
L1.3 ANSWER 55 OF 92 PCTFULL COPYRIGHT 2003 Univentio	ANSWER 58 OF 92 PCTFULL COPYRIGHT 2003 Univentio	L1.3 ANSWER 58 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1994023760 PCTFULL ED 20020513	TIEN METHOD FOR MODULATING TRANSENDOTHELIAL MIGRATION OF CELLS PROMOTING INFLAMMATION, AND RELATED METHODS OF MEASUREMENT THEREOF	AN 1994015641 PCTFULL ED 20020513
TIEN MODELE D'ANIMAL TRANSGENIQUE POUR MALADIES AUTOIMMUNES IN HARLAN, David, M.; JUNE, Carl, H.	TIFR PROCEDE DE MODULATION DE LA MIGRATION TRANSENDOTHELIALE DES CELLULES PAVORISANT L'INFLAMMATION ET PROCEDES CONNEXES DE MESURE DE CETTE MIGRATION	TIEN METHOD FOR MODULATING TRANSENDOTHELIAL MIGRATION
IN THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE NAVY PA English	IN MULLER, William, A.	IN MULLER, William, A.
LA DT Patent	WO 1994023760 A1 19941027 AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE	PA THE ROCKEFELLER UNIVERSITY;
PI WO 9423760	AI WO 1994-US1674 A 19940217	LA English
DS WO 1994-US1674	WO 1993-8/048,042 19930414	DT Patent
PRAI ICM	A61K057-00	WO 19940721
ICM A61K049-00; G01N033-48	C07H017-00; C12N005-00; C12N015-00; G01N031-00;	WO 9415641
ICM ICS		AU BB BG CA FI HU JP KP KR LK MG MN NO PL RO RU SD US CI CM GA GN ML MR NE SN TD CG
L1.3 ANSWER 56 OF 92 PCTFULL COPYRIGHT 2003 Univentio	ANSWER 59 OF 92 PCTFULL COPYRIGHT 2003 Univentio	AI 1994-US16 A 19940112
AN 199402614 PCTFULL ED 20020513	TIEN IMMUNE RESPONSE MODULATOR COMPLEX, AND USES THEREOF	AI 1993-8/003,258
TIEN ALLERGENIC PROTEIN AND PEPTIDES FROM HOUSE DUST MITE AND USES THEREFOR TIFR COMPLEXE MODULATEUR DE LA REPONSE IMMUNITAIRE, ET SES UTILISATIONS	TIEN ALLERGENIC PROTEIN AND PEPTIDES FROM HOUSE DUST MITE AND USES THEREFOR TIFR COMPLEXE MODULATEUR DE LA REPONSE IMMUNITAIRE, ET SES UTILISATIONS	AI 1994-US16 A 19940112
TIEN PROTEINE ET PEPTIDES ALLERGENES OBTENUS A PARTIR D'ACARIES DETRITICOLES IN THOMAS, Wayne, Robert; CHUA, Kaw-Yan	PIZZO, Salvatore, V.; CHU, Charleen, T.	AI 199401476 PCTFULL ED 20020513
IN THOMAS, Wayne, Robert; CHUA, Kaw-Yan	QURY, Tim, D.	PA IMMUNE RESPONSE MODULATOR COMPLEX, AND USES THEREOF
PA INSTITUTE FOR CHILD HEALTH RESEARCH; THOMAS, Wayne, Robert; CHUA, Kaw-Yan	DUKE UNIVERSITY;	PA PIZZO, Salvatore, V.; CHU, Charleen, T.
LA DT Patent	AT NU BB BG BR BY CA CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN NO NZ PL PT RO RU SD SE SI SK	PA PIZZO, Salvatore, V.; CHU, Charleen, T.
PI WO 9420614	A1 19940915	
DS W:		

LA DT P1 DS	OURY, Tim, D. English Patent WO 9414976	A1 19940707 AU BB BG BR BY CA C2 FI HU JP KP KR KZ LK MG MW NO NZ PL RO RU SD SK UA US VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL	AI PRAI ICM ICS	WO 1993-GB2492 GB 1992-925453, 1 GB 1993-930816, 7 GB 1993-9303634, 7 GB 1993-9319969, 3 C12N015-13 ICS	A 19931203 A 19921204 A 19931204 A 19931204 A 19931204 C07K015-28 : C12P021-08 ; C12N015-52 ; C12N015-70 ; C07K001-00
AI PRAI ICM ICS	ANSWER 60 OF 92 PTC FULL COPYRIGHT 2003 Un inventio US 1992-7/992,99 A 19931220 19921218 A61K047-48 ; GOIN033-569 ; C12N005-00 ; A61K039-395 ; A61K035-14	L1.3 T1EN TIFR	ANSWER 62 OF 92 PTC FULL COPYRIGHT 2003 Un inventio 1994010108 PCTFULL ED 20020513	AN T1EN TIFR	ANSWER 63 OF 92 PTC FULL COPYRIGHT 2003 Un inventio 19940109363 PCTFULL ED 20020513
IN PA LA DT PI DS	ANSWER 60 OF 92 PTC FULL COPYRIGHT 2003 Un inventio US 1994014467 PCTFULL ED 20020513 TRAITEMENT DE INFLAMMATORY BOWEL DISEASE WITH IFN-GAMMA INHIBITORS D'INTERFERON-GAMMA. ASHKENAZI, Avi, J.; WARD, Rebecca, H., R. GENENTECH, INC.; ASHKENAZI, Avi, J.; WARD, Rebecca, H., R.	L1.3 T1EN TIFR	ANSWER 63 OF 92 PTC FULL COPYRIGHT 2003 Un inventio 1994010308 PCTFULL ED 20020513	PI DS W: AI PRAI	ANSWER 63 OF 92 PTC FULL COPYRIGHT 2003 Un inventio 1994010308 PCTFULL ED 20020513
IN PA LA DT PI DS	ANSWER 61 OF 92 PTC FULL COPYRIGHT 2003 Un inventio US 1993-US11966 A 19931209 1992-7/997,835 19921229 A61K037-02 C07K015-00 ; C12N015-12	L1.3 T1EN TIFR	ANSWER 63 OF 92 PTC FULL COPYRIGHT 2003 Un inventio 1994013804 PCTFULL ED 20020513 MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE TIFR	PA LA IN PI DS W:	ANSWER 63 OF 92 PTC FULL COPYRIGHT 2003 Un inventio 1994013804 PCTFULL ED 20020513 MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE TIFR
IN PA LA DT PI DS	ANSWER 61 OF 92 PTC FULL COPYRIGHT 2003 Un inventio US 1994013804 PCTFULL ED 20020513 MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE TIFR	L1.3 T1EN TIFR	ANSWER 64 OF 92 PTC FULL COPYRIGHT 2003 Un inventio 1994013804 PCTFULL ED 20020513 MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE TIFR	PA LA IN PI DS W:	ANSWER 64 OF 92 PTC FULL COPYRIGHT 2003 Un inventio 1994013804 PCTFULL ED 20020513 MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE TIFR
IN PA LA DT PI DS	ANSWER 61 OF 92 PTC FULL COPYRIGHT 2003 Un inventio US 1994013804 PCTFULL ED 20020513 MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE TIFR	L1.3 T1EN TIFR	ANSWER 64 OF 92 PTC FULL COPYRIGHT 2003 Un inventio 1994013804 PCTFULL ED 20020513 MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE TIFR	PA LA IN PI DS W:	ANSWER 64 OF 92 PTC FULL COPYRIGHT 2003 Un inventio 1994013804 PCTFULL ED 20020513 MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE TIFR
IN PA LA DT PI DS	ANSWER 61 OF 92 PTC FULL COPYRIGHT 2003 Un inventio US 1994013804 PCTFULL ED 20020513 MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE TIFR	L1.3 T1EN TIFR	ANSWER 65 OF 92 PTC FULL COPYRIGHT 2003 Un inventio 1994009117 PCTFULL ED 20020513 DIRECT SELECTION OF CELLS BY SECRETION PRODUCT	PA LA IN PI DS W:	ANSWER 65 OF 92 PTC FULL COPYRIGHT 2003 Un inventio 1994009117 PCTFULL ED 20020513 DIRECT SELECTION OF CELLS BY SECRETION PRODUCT

TIFR IN	SELECTION DIRECTE DE CELLULES PAR UN PRODUIT DE SECRETION	L1.3 AN PCTFULL ED 20020513
PADBRUCH, Andreas; MANZ, Rudi	MILITENYI BIOTEC, INC.; MILITENYI, Stefan;	CD27 LIGAND LIGAND CD27 BECKMANN, M., Patricia; GOODWIN, Raymond, G.; GIRI, Judith, G.; ARMITAGE, Richard, J.
PA	PADBRUCH, Andreas;	IMMUNEX CORPORATION
LA	English	English
PT DS	WO 9409117 AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MV MN NO NZ PL PT RO RU SD SE SK UA US VN AT BE CH DE DK ES FR GB GR IE IT LU MC	WO 940561 AU CA FI JP KR NO NZ AT BE CH DE DK ES FR GB GR IE IT LU MC
AI PRAI ICM ICS	WO 1993-US10126 A 1992-7/955,334 A 19931021 A 19921021 A01N001-02; GO1N033-536; GO1N033-53; GO1N033-566; GO1N033-53;	WO 1993-US8223 A 19930901 US 1992-7/941,648 US 1993-8/106,507 C07H021-04 C07K013-00; C07K015-20; C12P021-06; C12N015-00
LA	ANSWER 66 OF 92 PCTFULL ED 20020513	ANSWER 69 OF 92 PCTFULL ED 20020513
TIEN	BISPECIFIC REAGENTS FOR REDIRECTED TARGETING OF LOW DENSITY LIPOPROTEIN	BISPECIFIC IMMUNOADSORPTIONS IMMUNOADSORPTIONS BISPECIFIQUES
TIFR IN	AGENTS BISPECIFIQUES DE REORIENTATION DU CIBLAGE DES LIPOPROTEINES DE FAIBLE DENSITE FANGER, Michael, W.;	ASHKENAZI, Avi, J.; CHANOW, Steven, M.
PA	TRUSTEES OF DARTMOUTH COLLEGE	GENENTECH, INC.
LA DT PI DS	WO 9408038 A1 19940414 AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE W: NO 1993-US9556 A 19931104 A 1992-7/955,681 PRAI ICM ICS	WO 9404690 AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE W: NO 1993-US7783 A 19930817 A 1992-7/921,811 C12N015-62 C12N015-13; C12N015-12; C07K015-28
LA	ANSWER 67 OF 92 PCTFULL ED 20020513	ANSWER 70 OF 92 PCTFULL ED 20020513
TIEN	RECOMBINANT VIRUSES DISPLAYING A NONVIRAL POLYPEPTIDE ON THEIR EXTERNAL SURFACE	METHODS AND COMPOSITIONS FOR INHIBITING ENDOTHELIAL CELL AND FIBRINOGEN PROCESSES ET COMPOSITIONS D'INHIBITION D'INFLAMMATIONS PROVOQUEES PAR DES CELLULES ENDOTHELIALES ET PAR LE FIBRINOGENE
TIFR IN	VIRUS RECOMBINES PRESENTANT UN POLYPEPTIDE NON-VIRAL SUR LEUR SURFACE EXTERNE	LANGUINO, Lucie, R.; ALTUBERI, Dario, C.; PLLOW, Edward, F.; GELTOSKY, John, E.
PA	RUSSELL, Stephen, James; HAWKINS, Robert, Edward; WINTER, Gregory, Paul MEDICAL RESEARCH COUNCIL;	THE SCRIPPS RESEARCH INSTITUTE
LA DT PI DS	WO 9406920 A1 19940331 AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN AT BE CH DE DK 'ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA	WO 9325218 A 19931223 W: NO 1993-US5610 A 19930611 A 1992-7/998,117 A61K037-00 A61K037-02; A61K037-04; A61K039-395; C07K007-00; C07K015-28;
AI PRAI ICM ICS	WO 1993-GB1992 A 19930922 GB 1992-922010.4 GB 1993-9304962.5 C12N015-86 A61K048-00; C12N015-10; C12N015-87; C12N015-6-2	ANSWER 71 OF 92 PCTFULL ED 20020513 MODIFIED CELLS AND METHOD OF TREATMENT CELLULES MODIFIEES ET PROCEDE DE TRAITEMENT EVAN, Gerard, Ian IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED; EVAN, Gerard, Ian

LA	English	OPPERMANN, Hermann	PA	Creative Biomolecules, Inc.;
DT	Patent	CETUS ONCOLOGY CORPORATION	LA	English
PI	WO 9320200	A1 19931014	DT	Patent
DS	GB 1992-9201275, 0	GB JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE	P1	WO 9316185
AI	WO 1993-GB616	A 19930402	DS	W: A 19930819
PRAI	GB 1992-9201275, 0	19920402	AI	WO 1993-US1055
ICM	GB 1992-9201276, 8	19920402	PRAI	A 19930205
TCM	CL2N015-12		ICM	W: 1992-831.967
ICS	CL2N015-11; CL2N015-62		ICM	CL2N015-13
L1.3	ANSWER 72 OF 92 PCTFULL COPYRIGHT 2003 Univentio		ICS	ICL0P021-08; C07K013-00; C07K015-28; C12N001-21;
AN	1993019196 PCTFULL ED 20020513			G01N033-574
TIEN	ANTI-CD3 AGLYCOSYLATED IGG ANTIBODY			
TIFR	ANTICORDS IgG ANTI-CD3 AGLYCOSYLED		L1.3	ANSWER 75 OF 92 PCTFULL COPYRIGHT 2003 Univentio
IN	BOLT, Sarah, Louise;		AN	1993011236 PCTFULL ED 20020513
	CLARK, Michael, Ronald;		TIEN	PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY
	GORMAN, Scott, David;		TIFR	SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
	ROUTLEDGE, Edward, Graham;		IN	PRODUCTION D'ANTICORPS ANTI-AUTO-ANTIGENES A PARTIR DE REPERTOIRES DE
	WALDMANN, Herman			SEGMENTS D'ANTICORPS AFFICHES SUR PHAGE
	BOLT, Sarah, Louise;			GRIFFITHS, Andrew, David;
PA	CLARK, Michael, Ronald;			HOOGENBOOM, Hendricus, Renerus, Jacobus, Matthews;
	GORMAN, Scott, David;			MARKS, James, David;
	ROUTLEDGE, Edward, Graham;			MCCAFFERTY, John;
	WALDMANN, Herman			WINTER, Gregory, Paul;
LA	English			GRIGG, Geoffrey, Walter
DT	Patent			GRIGG, Geoffrey, Walter
PI	WO 9319196	A1 19930930	LA	Medical Research Council;
DS	AU CA JP KR IE IT LU MC NL SE		DT	CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED;
AI	WO 1992-GB1933	A 19921021	P1	GRIFFITHS, Andrew, David;
PRAI	GB 1992-9206422, 9	19920324	DS	HOOGENBOOM, Hendricus, Renerus, Jacobus, Matthews;
ICM	CL2P021-08			MARKS, James, David;
ICS	A61K039-395			MCCAFFERTY, John;
L1.3	ANSWER 73 OF 92 PCTFULL COPYRIGHT 2003 Univentio			WINTER, Gregory, Paul;
AN	1993017715 PCTFULL ED 20020513			GRIGG, Geoffrey, Walter
TIEN	DIAGNOSTIC AND/OR THERAPEUTIC AGENTS, TARGETED TO NEOVASCULAR			English
TIFR	ENDOTHELIAL CELLS			
IN	AGENTS DIAGNOSTIQUES ET/OU THERAPEUTIQUES CIBLES SUR DES CELLULES			
	ENDOTHELIALES NEOVASCULAIRES			
THORPE, Philip, E.;				
BURROWS, Francis, J.				
PA	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM;			
	IMPERIAL CANCER RESEARCH TECHNOLOGY;			
	THORPE, Philip, E.;			
	BURROWS, Francis, J.			
LA	English			
DT	Patent			
PI	WO 9317715	A1 19930916		
DS	AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CG CI CM GA GN ML MR SN TD TG		L1.3	ANSWER 76 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AI	WO 1993-US1956	A 19930305	AN	1993009803 PCTFULL ED 20020513
PRAI	US 1992-7'846, 349	19920305	TIEN	FACTOR X-DEIVED POLYPEPTIDES AND ANTI-PEPTIDE ANTIBODIES,
ICM	A61K047-48		TIFR	SYSTEMS AND THERAPEUTIC METHODS FOR INHIBITING INFLAMMATION,
ICS	A61K049-00; A61K049-02		IN	PROCEDES THERAPEUTIQUES SERVANT A INHIBER L'INFLAMMATION
L1.3	ANSWER 74 OF 92 PCTFULL COPYRIGHT 2003 Univentio			ALTIERI, Dario, C.;
AN	1993016185 PCTFULL ED 20020513			EDINGTON, Thomas, S.;
TIEN	BIOACTIVE BINDING PROTEIN FOR CANCER MARKER			FAIR, Daryl, S.; +di
TIFR	PROTEINE DE LIAISON BIOSYNTHETIQUE POUR MARQUEUR DE CANCER			SCHAFFER, Susan, C.; +ef;
IN	HUSTON, James, S.;			THE SCRIPPS RESEARCH INSTITUTE;
	HOUSTON, L., L.;			ALTIERI, Dario, C.;
	RING, David, B.;			EDINGTON, Thomas, S.
LA	English			English
DT	Patent			
PI	WO 9309803			Patent
				A1 19930527

DS	W:	AU CA FI JP NO US AT BE CH DE DK ES FR GB GR IE IT LU MC NL		L1.3	ANSWER 80 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AI	WO 1992-US10068 US 1991-7/78,221	A 19921120 19911122		AN 199101758 PCTFULL ED 20020513	TIEN INHIBITEURS DE FACTEUR XII ACTIVATION AND APPLICATIONS THEREOF
PRAI	US 1991-7/78,221			TIFR INHIBITEURS DE L'ACTIVATION DU FACTEUR XII ET LEURS APPLICATIONS	
ICM	C07K007-06;	C07K007-08;	C07K007-10	IN NULIENS, Jan. H.;	
ICS				HUIJBREETS, Cecile, C., M.;	
				HACK, C., Erik	
				CETUS CORPORATION;	
				NULIENS, Jan. H.;	
				HUIJBREETS, Cecile, C., M.;	
				HACK, C., Erik	
				English	
				Patent	
				PT WO 9117258 A1 19911114	
				DS W: AT AU BE CA CH DE DK ES FR GB GR IT JP LU NL SE	
				AI WO 1991-US2590 A 19910501	
				PRAI US 1990-521.820 19900510	
				ICM C12P021-08	
				ICS C07K15-00; A61K039-395; C07K007-08	
PA	ANSWER 77 OF 92 PCTFULL COPYRIGHT 2003 Univentio			L1.3	ANSWER 81 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN	199300056 PCTFULL ED 20020513			AN 1991012022 PCTFULL ED 20020513	TIEN IMMUN COMPLEXES
				DS TAKEDA CHEMICAL INDUSTRIES, LTD. ;	
TIEN	HYBRID PROTEINS CONTAINING BINDING SITES			AI HAMAGUCHI, Naofu;	
TIFR	PROTEININES HYBRIDES RENFERMANDES SITES DE LIASION			IN SATO, Jun.;	
IN	LERNHARDT, Waltemar;			DOKEN, Kazuhiro;	
	BOURDON, Mario;			IWASA, Susumu	
	YOUSDERIAN, Phil;			PA TAKEDA CHEMICAL INDUSTRIES, LTD. ;	
	CALIFORNIA INSTITUTE OF BIOLOGICAL RESEARCH;			TIEN HAMAGUCHI, Naofu;	
	LERNHARDT, Waltemar;			IN SATO, Jun.;	
	BOURDON, Mario;			DOKEN, Kazuhiro;	
	YOUSDERIAN, Phil;			IWASA, Susumu	
	English			LA English	
	Patent			DT Patent	
PI	WO 9100356	A1 19930107		PT WO 91120322 A1 19910822	
DS	CA JP US AT BE CH DE DK ES FR GB GR IT LU MC NL SE			DS W: AT BE CA CH DE DK ES FR GB GR IT JP KR LU NL SE US	
AI	WO 1992-US5724	A 19920619		AI WO 1991-JP136 A 19910205	
PRAI	US 1991-720,222			PRAI JP 1990-2/27407 19900206	
ICM	C07K003-00			ICM JP 1990-2/28182 19900328	
ICS	C07K013-00; C12P021-00			ICM A61K047-48 19901024	
				ICS A61K039-44; A61K037-52	
PA	ANSWER 78 OF 92 PCTFULL COPYRIGHT 2003 Univentio			L1.3	ANSWER 82 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN	199206193 PCTFULL ED 20020513			AN 199100874 PCTFULL ED 20020513	TIEN CYTOKINE ANTIBODY FOR THE TREATMENT OF SEPSIS
				DS TIFR ANTICORPS DE CYTOKINE UTILISE DANS LE TRAITEMENT DE LA	
TIEN	ANTIBODIES DIRECTED AGAINST CD3			AI SEPTICEMIE	
TIFR	ANTICORPS A EFFICACITE ANTIGONISTE A L'ANTIGENE CD3			IN AARDEN, Lucien, A.;	
IN	GORMAN, Scott, David;			PA CREESEY, Alja, A.;	
	ROUTLEDGE, Edward, Graham;			PA KOTHS, Kirson, E.;	
	WALDMANN, Herman			PA CETUS CORPORATION;	
	ROUTLEDGE, Edward, Graham;			PA AARDEN, Lucien, A.	
	English			LA English	
	Patent			DT Patent	
PI	WO 9206193	A1 19920416		PT WO 9108774 A1 19910627	
DS	AT AU BE CA CH DE DK ES FR GB GR IT JP KR LU NL SE US			DS W: AT AU BE CA CH DE DK ES FR GB GR IT JP LU NL SE	
AI	1991-GB1726	A 19911004		AI WO 1990-US741 A 19901213	
PRAI	GB 1990-9021679, 7	19901005		PRAI US 1989-451,218 19891215	
ICM	C12N015-13			ICM A61K039-395	
ICS	C12P015-28; C12P021-08; A61K039-395			ICM C12P021-08; C07K015-28	
PA	ANSWER 79 OF 92 PCTFULL COPYRIGHT 2003 Univentio			L1.3	ANSWER 83 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN	199206121 PCTFULL ED 20020513			AN 1991006319 PCTFULL ED 20020513	TIEN ANGIGEN-ANTIBODY CONJUGATES
				DS TIFR CONJUGUES ANTIGENES-ANTICORPS	
TIEN	ANTIGEN-ANTIBODY CONJUGATES			AI NASON, Donald, William	
TIFR	CONJUGUES ANTIGENES-ANTICORPS			PA MEDICAL RESEARCH COUNCIL;	
IN	MASON, Donald, William			PA NASON, Donald, William	
	Medical Research Council			LA English	
	English			DT Patent	
PA	ANSWER 80 OF 92 PCTFULL COPYRIGHT 2003 Univentio			PT WO 9108774 A1 19910627	
DS	AT AT AU BB BE BF BG BR CA CF CG CH CI CM CS DE DE DK			DS W: AT AU BE CA CH DE DK ES FR GB GR IT JP LU NL SE	
	DK ES ES FI FR GA GB GN GR HU IT JP KP KR LK LU MC MG			AI WO 1990-US741 A 19901213	
	ML MN MR MW NL NO PL RO SD SE SN SU TD TG US			PRAI US 1989-451,218 19891215	
AI	WO 1991-GB1641	A 19910924		ICM A61K039-395	
PRAI	GB 1990-9021210, 1	19900928		ICM C12P021-08; C07K015-28	
ICM	GB 1991-9110444, 8	19910514			
ICS	C07K017-02				

- TIEN METHODS AND COMPOSITIONS FOR PROMOTING IMMUNOPOTENTIATION
TIFR PROCÉDÉS ET COMPOSITIONS DE PROMOTION DE L'IMMUNOPOTENTIATION
IN BLUESTONE, Jeffery, A.
PA ARCH DEVELOPMENT CORPORATION
LA English
DT Parent
PI WO 9106319 A1 19910516
DS AT AT AU BB BE BF BG BJ BR CA CF CG CH CM DE DE DK DK ES
W: ES FI FR GA GB GB CR HU IT JP KP KR LK LU MC MG ML MR MW
AI WO 1990-US6177 A1 19901026
PRAI US 1989-429,729 19891027
ICM A61K039-39
ICS A61K037-02; C07K015-00; A61K039-00; C12P021-08; A61K039-395;
A61K037-02
- L13 ANSWER 84 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1991002756 PCTFULL ED 20020513
TIEN PROHORMONE CLEAVAGE SITE BLOCKING ANTIBODY
TIFR ANTICORPS PROHORMONE POUR BLOCAGE DU SITE DE CLIVAGE
IN KRUGLER, Michael;
PEREZ, Carl;
PA CETUS CORPORATION
LA English
DT Patent
PI WO 9102756 A1 19910307
DS W: AT AU BE CH DE DK ES FR GB IT JP LU NL SE
AI WO 1990-US4536 A 19900813
PRAI US 1989-395, 254
ICM C07K015-28
ICS A61K039-395; G01N33-74; C12P021-08
- L13 ANSWER 85 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1991000360 PCTFULL ED 20020513
TIEN BISPECIFIC REAGENTS FOR AIDS THERAPY
TIFR REACTIFS BISPECIFIQUES POUR LE TRAITEMENT DU SIDA
IN FANGER, Michael, W.;
GUYER, Paul, M.;
DINCES, Nathan, B.
PA MEDAREX, INC.
DT Parent
PI WO 9100360 A1 19910110
DS W: AT AU BE CA CH DE DK ES FI FR GB IT JP LU NL NO SE
AI WO 1990-US751 A 19900629
PRAI US 1989-373, 905
ICM C12P021-00
ICS C12N005-00; A61K039-395
- L13 ANSWER 86 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 951804167 SCISEARCH Number: TE709
TI THE PERFORMANCE OF CD3XCD19 BISPECIFIC MONOCLONAL-ANTIBODIES
AU IN B-CELL MALIGNANCY
CS UNIV Utrecht HOSP, DEPT IMMUNO, F03821, POSTBUS 85500, 3508 GA Utrecht,
NETHERLANDS (Reprint)
CYA NETHERLANDS
SO LEUKEMIA & LYMPHOMA, (NOV 1995) Vol. 19, No. 5-6, pp. 381-393.
ISSN: 1042-8194.
DT General Review; Journal
FS LIFE; CLIN
LA ENGLISH
REC No References Keyed

* ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

- L13 ANSWER 87 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 95149351 SCISEARCH Number: RJ663
GA The Genuine Article (R) Number: RJ663
TI CD8 T-CELL ACTIVATION AFTER INTRAVENOUS ADMINISTRATION OF CD3XCD19
BISPECIFIC ANTIBODY IN PATIENTS WITH
NON-HODGKIN-LYMPHOMA
AU DEGASST G C (Reprint); HAAGEN I A; VANHOUTEN A A; KLEIN S C; DUITJ A J;
DEVEGER R A; VROOM T M; CLARK M R; PHILLIPS J; VANDLUK A J G; DELAU W B M;
BAST B J E G
CS UNIV Utrecht HOSP, DEPT HAEMATOL, POB 85500, 3508 GA Utrecht, NETHERLANDS
(Reprint); UNIV Utrecht HOSP, DEPT IMMUNOL, Utrecht, NETHERLANDS; UNIV
UTRECHT HOSP, DEPT PATHOL, 3508 GA Utrecht, NETHERLANDS; UNIV CAMBRIDGE,
DEPT PATHOL, CAMBRIDGE, ENGLAND
CYA SO CANCER IMMUNOLOGY IMMUNOTHERAPY, (JUN 1995) Vol. 40, No. 6, pp. 390-396.
ISSN: 0340-7004
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 37
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
- L13 ANSWER 88 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 95197058 SCISEARCH
TI BI-SPECIFIC MONOCLONAL-ANTIBODY THERAPY OF B-CELL MALIGNANCY
AU WEINER G J (Reprint); DEGAST G C
CS UNIV IOWA, DEPT INTERNAL MED, C32K GH, IOWA CITY, IA, 52242 (Reprint)
CYA SO LEUKEMIA & LYMPHOMA, (JUN 1995) Vol. 16, No. 3-4, pp. 199-207.
ISSN: 1042-8194.
DT General Review; Journal
FS LIFE; CLIN
LA ENGLISH
REC No References Keyed
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
- L13 ANSWER 89 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 941329243 SCISEARCH
TI THE ROLE OF T-CELL SUBSETS IN THE BISPECIFIC ANTIBODY
DEMANET C; BRISSINCK J; LEE O; MOSER M; THIELEMANS K (Reprint)
FREE UNIV BRUSSELS, SCH MED, PHYSIOL LAB, LAARBEKELAAN 103-E, B-1090
BRUSSELS, BELGIUM (Reprint); FREE UNIV BRUSSELS, SCH MED, PHYSIOL LAB,
B-1090 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, B-1060 RHODE ST GENÈSE,
BELGIUM
CYA SO CANCER RESEARCH, (01 JUN 1994) Vol. 54, No. 11, pp. 2973-2978.
ISSN: 0008-5672
DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 33
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
- L13 ANSWER 90 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 931729696 SCISEARCH
TI BI-SPECIFIC ANTIBODY (CD3/CD19, SHR-1) - A PHASE-I STUDY
IN PATIENTS WITH CD19 POSITIVE B-CELL MALIGNANCIES

- AU VANHOUTEN A A (Reprint); HAAGEN I A; CLARK M; GEERARS A; DELAU W; VROOM T M; BAST E J E G; DEGAST G C
CS Utrecht Hosp, Dept Hematol, 3511 GV Utrecht, Netherlands; Univ Utrecht Hosp, Dept Immunol, 3511 GV Utrecht, Netherlands; Univ Utrecht Hosp, Dept Pathol, Cambridge, England
CYA SO BLOOD, (05 NOV 1993) Vol. 82, No. 10, Supp. 1, pp. A580.
DT Conference; Journal
FS LIFE; CLIN
LA ENGLISH
REC No References
- L1.3 ANSWER 91 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 93:45451 SCISEARCH
GA The Genuine Article (R) Number: LN208
TI CD30-SPECIFIC TARGETING AND ACTIVATION OF T-CELLS VIA MURINE BISPECIFIC MONOCLONAL-ANTIBODIES AGAINST CD3 AND CD28 - POTENTIAL USE FOR THE TREATMENT OF HODGKINS LYMPHOMA
AU POHL C; DENFELD R; RENNER C; JUNG W; BOHLEN H; SAHIN U; HOMBACH A; VANLIER R; SCHWONEN M; DIEHL V; PEREINDUSCHUH M (Reprint)
CS UNIV GARLAND, MED KLIN 1, W-6650 HOMBURG, GERMANY; UNIV COLOGNE, INNERE MED KLIN 1, W-5000 COLOGNE 41, GERMANY; NCB, AMSTERDAM, NETHERLANDS
CYA SO INTERNATIONAL JOURNAL OF CANCER, (09 JUL 1993) Vol. 54, No. 5, pp. 820-827.
ISSN: 0020-7136.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 32
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
- L1.3 ANSWER 92 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 92:687393 SCISEARCH
GA The Genuine Article (R) Number: JY980
TI TARGETED CYTOKINE PRODUCTION
AU SEGAL D M (Reprint); QIAN J H; TITUS J A; MORENO M B; GEORGE A J T; JUST C
CS NIH, EXPTL IMMUNOL BRANCH, BLDG 10, ROOM 4B17, BETHESDA, MD, 20892
(Reprint)
CYA SO INTERNATIONAL JOURNAL OF CANCER, (1992) Supp. 7, pp. 36-38.
ISSN: 0020-7136.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 21
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
- => d 90, 88, 86, 82, 61 ibid ab
- L1.3 ANSWER 90 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
ACCESSION NUMBER: 93:729656 SCISEARCH
THE GENUINE ARTICLE: MJ682
TITLE: CYTOKINE RELEASE AFTER INTRAVENOUS ADMINISTRATION OF ISPECIFIC ANTIBODY (CD3/CD19, SHR-1) - A PHASE-I STUDY IN PATIENTS WITH CD19 POSITIVE B-CELL MALIGNANCIES
AUTHOR: VANHOUTEN A A (Reprint); HAAGEN I A; CLARK M; GEERARS A;
CORPORATE SOURCE: DELAU W; VROOM T M; BAST E J E G; DEGAST G C
UNIV Utrecht Hosp, Dept Hematol, 3511 GV Utrecht, Netherlands; Univ Utrecht Hosp, Dept Immunol, 3511 GV
- UTRECHT, NETHERLANDS; UNIV Utrecht Hosp, Dept Pathol, 3511 GV Utrecht, Netherlands; Univ Cambridge, Dept Pathol, Cambridge, England
COUNTRY OF AUTHOR:
SOURCE: BLOOD, (15 NOV 1993) Vol. 82, No. 10, Supp. 1, pp. A580.
DOCUMENT TYPE:
FILE SEGMENT:
LANGUAGE:
REFERENCE COUNT: 0
- L1.3 ANSWER 88 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
ACCESSION NUMBER: 95:97856 SCISEARCH
THE GENUINE ARTICLE: QC930
TITLE: BI-SPECIFIC MONOCLONAL-ANTIBODY THERAPY OF B-CELL MALIGNANCY
AUTHOR: WEINER G J (Reprint); DEGAST G C
COUNTRY OF AUTHOR: UNIV IOWA, DEPT INTERNAL MED., C32K GH, IOWA CITY, IA,
USA
SOURCE: LEUKEMIA & LYMPHOMA, (JAN 1995) Vol. 16, No. 3-4, pp. 522-522 (Reprint)
ISSN: 1042-8194.
DOCUMENT TYPE:
FILE SEGMENT:
LANGUAGE:
REFERENCE COUNT: 0
- AB Bi-specific monoclonal antibodies (bsabs) that recognize CD3 with one arm and tumor associated antigen with the other arm can retarget T-cells toward tumor cells in an MHC independent manner, thereby combining the specificity of monoclonal antibodies with the power of the cellular immune system. B-cell malignancies are particularly attractive targets for anti-CD3-based bsab therapy because of their sensitivity to antibody therapy, and the extent to which B-cells and T-cells communicate at the molecular level. Bsabs that recognize CD3 and number of antigens on malignant B cells have been shown in vitro to be capable of retargeting T-cells. In animal models of B-cell malignancy, bsab can eliminate tumor loads that are resistant to unmodified monoclonal antibody therapy. Ongoing early clinical trials in advanced B-cell lymphoma indicate CD3-based bsabs have significant biologic effects, and suggest they have anti-tumor activity as well. A number of significant questions relating to bsab therapy of B-cell malignancies remain. It is unclear what role both endogenously produced and exogenously administered cytokines are likely to play. Further exploration of whether bsab can induce T-cells to target to tumor will also be required before the true promise of this novel form of immunotherapy can be determined.
- L1.3 ANSWER 86 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
ACCESSION NUMBER: 95:004167 SCISEARCH
THE GENUINE ARTICLE: TE709
TITLE: PERFORMANCE OF CD3XCD19 BISPECIFIC MONOCLONAL-ANTIBODIES IN B-CELL MALIGNANCY
AUTHOR: HAAGEN I A (Reprint)
COUNTRY OF AUTHOR:
SOURCE: 3508 GA Utrecht, Dept Immunol F03821, Postbus 85500, NETHERLANDS (Reprint)
COUNTRY OF AUTHOR:
SOURCE: LEUKEMIA & LYMPHOMA, (NOV 1995) Vol. 19, No. 5-6, pp. 381-393.
ISSN: 1042-8194.
DOCUMENT TYPE:
General Review; Journal

FILE SEGMENT : LIFE; CLIN
 LANGUAGE : ENGLISH
 REFERENCES COUNT : No References Keved
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

AB. Bispecific monoclonal antibodies, with a dual specificity for tumor associated antigens on target cells and for surface markers on immune effector cells, have been shown (in vitro) to be effective in direct and triggering effector cells to kill target cells resulting in target cell lysis. Bispecific monoclonal antibodies (BsAb) against the CD3 antigen on T cells and the CD19 antigen on B cell were developed. Data obtained by in vitro experiments might indicate that clinical responses in BsAb immunotherapy, will only be obtained in patients with minimal tumor load and may need additional T cell stimulation via cytokines such as IL-2. Although these experiments have shown us their limitations, they also include the promise of BsAb-directed immunotherapy in B cell malignancy as further demonstrated during a Phase I trial, showing little toxicity. Clearly, much remains to be done before this BsAb is routinely used for therapy, but, the results presented show that the cell malignancy. This report describes the experiments performed to test a new immunotherapeutic approach for the treatment of B cell malignancy. Bispecific antibodies are described that can target cytotoxic T cells to tumor cells and elicit a cytolytic action towards these cancer cells.

L13 ANSWER 82 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER : 199108774 PCTFULL ED 20020513
 TITLE (ENGLISH) : CYTOKINE ANTIBODY FOR THE TREATMENT
 OF SEPSIS

TITLE (FRENCH) : ANTICORPS DE CYTOKINE UTILISE DANS LE
 TRAITEMENT DE LA SEPTICEMIE

INVENTOR(S) : AARDN, Lucien, A.;
 CREESEY, Abla, A.;
 KOTHIS, Kirston, E.
 CETUS CORPORATION;
 AARDN, Lucien, A.
 English
 Patent

PATENT ASSIGNEE(S) :
 LANGUAGE OF PUBL. :
 DOCUMENT TYPE :
 PATENT INFORMATION :
 NUMBER : WO 9108774 DATE : Al 19910627

DESIGNATED STATES W:
 APPLICATION INFO. : AT AU BE CA CH DE DK ES FR GB IT JP LU NL SE
 PRIORITY INFO. : WO 1990-US7411 A 19901213
 ABEN Compositions and methods for prophylactically or therapeutically treating sepsis consisting of antibody to IL-6 and/or M-CSF wherein the antibodies are administered alone or in combination.

ABFR Compositions et procedes de traitements prophylatiques ou therapeutiques de la septicemie, comprenant un anticorps contre IL-6 et/ou les facteurs de croissance de macrophages, dans lesquels les anticorps sont administres seuls ou de maniere combinee.

L13 ANSWER 61 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER : 1994013804 PCTFULL ED 20020513
 TITLE (ENGLISH) : MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR
 MANUFACTURE AND USE
 TITLE (FRENCH) : PROTEINES DE LIASION MULTIVALENTES ET MULTISPECIFIQUES,
 LEUR FABRICATION ET LEUR UTILISATION

INVENTOR(S) : HOLLIGER, Kaspar-Philipp;
 GRIFFITHS, Andrew, David;

HOOGENBOOM, Hendricus, Renerus, Jacobus, Matheus;
 MALMOVIST, Magnus;
 MARKS, James, David;
 MCQUINNESS, Brian, Timothy;
 POPE, Anthony, Richard;
 PROSPERO, Terence, Derek;
 WINTER, Gregory, Paul
 CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED;
 MEDICAL RESEARCH COUNCIL;
 HOLLIGER, Kaspar-Philipp;
 GRIFFITHS, Andrew, David;
 HOOGENBOOM, Hendricus, Renerus, Jacobus, Matheus;
 MALMOVIST, Magnus;
 MARKS, James, David;
 MCQUINNESS, Brian, Timothy;
 POPE, Anthony, Richard;
 PROSPERO, Terence, Derek;
 WINTER, Gregory, Paul
 English
 Patent

PATENT ASSIGNEE(S) :
 LANGUAGE OF PUBL. :
 DOCUMENT TYPE :
 PATENT INFORMATION :
 NUMBER : WO 9413804 DATE : Al 19940623

DESIGNATED STATES W:
 AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR
 KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA
 US U2 VN AT BE DE DK ES FR GB GR IE IT LU MC NL PT
 SE BU CF CG CI CM GA GN ML MR NE SN TD TG
 WO 1993-GB2492 A
 PRIORITY INFO. :
 GB 1992-9225453, 1
 GB 1993-9300816, 7
 GB 1993-93303614, 7
 GB 1993-9319969, 3
 GB 1993-9319922

ABEN Polypeptides comprising a first domain, which comprises a binding region of an immunoglobulin heavy chain variable region, and a second domain, which comprises a binding region of an immunoglobulin heavy chain variable region, the domains being linked but incapable of associating with each other to form an antigen binding site, associate to form antigen binding multimers, such as dimers, which may be multispecific or have multispecificity. The domains may be linked by a short peptide linker or may be joined directly together. Bispecific dimers may have longer linkers.

Methods of preparation of the polypeptides and multimers and diverse repertoires thereof, and their display on the surface of bacteriophage for easy selection of binders of interest, are disclosed.

ABFR Des polypeptides comprenant un premier domaine presentant une region de fixation de la region variable d'une chaine lourde d'immunoglobuline, et un deuxième domaine presentant une region de fixation de la region variable d'une chaine legere d'immunoglobuline, les deux domaines etant lies mais incapables de s'associer pour former un site de fixation d'antigene, s'associer pour former des multimers de fixation d'antigene tels que des dimeres, lesquels peuvent etre multivalents ou a specifique multiple. Les domaines peuvent etre lies par un lieu peptide court ou unis directement. Les dimeres bispecifiques peuvent avoir des lieux plus longs. Des procedes de

préparation desdits polypeptides et multimeres ainsi que de leurs divers répertoires leur utilisation à la surface d'un bactériophage afin de faciliter la sélection des lieux selon l'invention ainsi que leurs nombreuses applications sont décrites.

=>
Logging off of STN--

Connection closed by remote host
END
Unable to generate the STN prompt.
Exiting the script...